Materiały źródłowe

• #1

  https://www.nhs.uk/conditions/non-hodgkin-lymphoma/treatment/

  Non-Hodgkin lymphoma is usually treated with chemotherapy or radiotherapy, although some people may not need treatment straight away. […] The recommended treatment plan will depend on your general health and age, as many of the treatments can put a strain on the body. […] Discussions about your treatment plan will usually take place with several doctors and other health professionals who specialise in different aspects of treating lymphoma. […] Your MDT will recommend the best treatment options for you. […] If non-Hodgkin lymphoma is low grade (slow developing) and you’re well, a period of „watch and wait” is often recommended. […] Chemotherapy is a widely used treatment for non-Hodgkin lymphoma that involves using medicine to kill cancer cells. […] It may be used on its own, combined with biological therapy, or combined with radiotherapy.

• #2 Treatment options for non-Hodgkin lymphoma | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/treatment/decisions

  A team of healthcare professionals decide if you need treatment straight away. They also decide what your treatment options are. The most common treatment options for non-Hodgkin lymphoma (NHL) are: chemotherapy, targeted and immunotherapy cancer drugs, steroids, radiotherapy, stem cell transplant. Your treatment depends on what type of NHL you have. […] Your MDT usually includes: a haematologist – a doctor specialising in blood cancers, a specialist haematology nurse – also called a clinical nurse specialist (CNS), a pathologist – a doctor who diagnoses diseases from examining lymph node biopsies, a clinical oncologist – a doctor specialising in radiotherapy treatment, a pharmacist, a radiologist a doctor specialising in reading x-rays and scans. […] If you need treatment, your team plans it depending on: your type of NHL, how fast your NHL is growing – this is the grade, how many places in your body are affected by NHL and where these are this is the stage, your general health, your age.

• #3 Non-Hodgkin Lymphoma Treatment – NCI

  https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq

  Non-Hodgkin lymphoma is a disease in which malignant (cancer) cells form in the lymph system. […] Non-Hodgkin lymphoma can be indolent or aggressive. […] The treatments for indolent and aggressive lymphoma are different. […] Treatment is needed if signs or symptoms occur after the cancer disappeared or after initial cancer treatment. […] Treatment for non-Hodgkin lymphoma may cause side effects. […] The following types of treatment are used: Radiation therapy, Chemotherapy, Immunotherapy, Targeted therapy, Plasmapheresis, Watchful waiting, Antibiotic therapy, Surgery, Stem cell transplant. […] For pregnant women with non-Hodgkin lymphoma, treatment is carefully chosen to protect the fetus. […] Treatment decisions are based on the mother’s wishes, the stage of the non-Hodgkin lymphoma, and the trimester of the pregnancy.

• #4 Non-Hodgkin lymphoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/diagnosis-treatment/drc-20375685

  Non-Hodgkin lymphoma treatment often starts with medicines or radiation therapy. Medicines used for this cancer include chemotherapy, immunotherapy and targeted therapy. […] The treatments your healthcare team chooses for you depend on your lymphoma. Your healthcare team considers the types of cells involved and how quickly the cancer is growing. Your team also considers your overall health and what you prefer. […] If your lymphoma seems to be growing slowly and doesn’t cause symptoms, you might not need treatment right away. Instead, you may have checkups every few months. The checkups help your healthcare team watch your condition and see if your cancer is growing. […] Chemotherapy treats cancer with strong medicines. There are many chemotherapy medicines. Most chemotherapy medicines are given through a vein. Some come in pill form.

• #5 4 Innovative Non-Hodgkin Lymphoma Treatment Options | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/non-hodgkin-lymphoma/non-hodgkin-lymphoma-treatment.html

  MD Anderson is committed to helping people with non-Hodgkin lymphoma live longer, healthier lives and were making great strides toward advanced therapies that minimize side effects. […] We have found the most successful way to treat indolent (slow-growing) Non-Hodgkin lymphoma often is with strategies that limit or avoid the use of chemotherapy and have less impact on your body. […] Your treatment for non-Hodgkin lymphoma cancer will be customized to your particular needs. One or more of the following therapies may be recommended to treat the cancer or help relieve symptoms. […] Chemotherapy kills fast-growing cells, including cancer cells. This is the treatment most often used for non-Hodgkin lymphoma. […] Radiation therapy uses focused beams of energy to kill cancer cells. Radiation therapy may be used in early-stage lymphoma or to help symptoms such as pain.

• #6 Treatments for non-Hodgkin lymphoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment

  Your healthcare team will create a treatment plan just for you. The plan is based on your health and specific information about the cancer. What you want is also important when planning treatment. When deciding which treatments to offer for non-Hodgkin lymphoma (NHL), your healthcare team will consider: […] When planning treatment, the healthcare will look at if the NHL is an indolent or aggressive type. […] Indolent NHL means that the cancer is growing slowly. Because it grows slowly, some people will only ever need watchful waiting. If other treatments are used, like chemotherapy or targeted therapy, indolent NHLs usually respond well to treatment and can often be controlled for many years. […] Aggressive NHL means that the cancer is growing quickly. An aggressive NHL often causes symptoms soon after it develops, and these symptoms usually need to be treated right away. Aggressive NHLs usually respond well to treatment.

• #7 Non-Hodgkin lymphoma (NHL) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin

  Some types of NHL grow very slowly and may not need treatment for months or years. Other types grow quickly and need treatment soon after diagnosis. […] A team of specialists will meet to discuss the best possible treatment for you. This is called a multidisciplinary team (MDT). […] There are different types of treatment for NHL. You may need just one type of treatment or a combination of treatments. […] Your doctor or cancer specialist or nurse will explain the different treatments and their side effects. They will also talk to you about things to consider when making treatment decisions. […] Treating lymphoma will depend on: the type of lymphoma and the stage and grade of the lymphoma. […] Types of treatment you may have include: Watch and wait, Chemotherapy, Steroids, Targeted therapies, Radiotherapy, Stem cell transplant. […] You may have some treatments as part of a clinical trial. […] We have more information about treating non-Hodgkin lymphoma.

• #8 Non-Hodgkin Lymphoma: Treatment Choices | Saint Luke’s Health System

  https://www.saintlukeskc.org/health-library/non-hodgkin-lymphoma-treatment-choices

  There are many treatment choices for non-Hodgkin lymphoma. The one that’s best for you depends on things such as: […] Treatment for cancer is either local or systemic. Systemic treatment is most often used for lymphoma, but you may have both. […] Treatment may control or cure the lymphoma. It can also improve your quality of life by helping to control symptoms of the disease. The goal of non-Hodgkin lymphoma treatment is to do one or more of these things: […] Here’s a list of common non-Hodgkin lymphoma treatments: […] Chemotherapy (chemo). This is the use of strong medicines to treat cancer. It’s often the main treatment for non-Hodgkin lymphoma. One or more medicines might be used to kill lymphoma cells all over your body. Chemo might be given along with other types of treatment.

• #9

  https://www.nhs.uk/conditions/non-hodgkin-lymphoma/treatment/

  Non-Hodgkin lymphoma is usually treated with chemotherapy or radiotherapy, although some people may not need treatment straight away. […] The recommended treatment plan will depend on your general health and age, as many of the treatments can put a strain on the body. […] Discussions about your treatment plan will usually take place with several doctors and other health professionals who specialise in different aspects of treating lymphoma. […] Your MDT will recommend the best treatment options for you. […] If non-Hodgkin lymphoma is low grade (slow developing) and you’re well, a period of „watch and wait” is often recommended. […] Chemotherapy is a widely used treatment for non-Hodgkin lymphoma that involves using medicine to kill cancer cells. […] It may be used on its own, combined with biological therapy, or combined with radiotherapy.

• #10 Treatments for non-Hodgkin lymphoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment

  For some types of NHL, your healthcare team may use imaging tests to check how the cancer is responding to treatment. […] Chemotherapy uses drugs to destroy cancer cells. Non-Hodgkin lymphoma (NHL) is often treated with chemotherapy. […] Targeted therapy uses drugs to target specific molecules on cancer cells. Non-Hodgkin lymphoma (NHL) is usually treated with targeted therapy. […] Watchful waiting may be offered for non-Hodgkin lymphoma (NHL). The healthcare team watches the cancer closely to see if it is growing before offering other treatments. […] Non-Hodgkin lymphoma (NHL) is sometimes treated with immunotherapy. It helps strengthen the immune system to fight cancer. […] A stem cell transplant replaces stem cells. Non-Hodgkin lymphoma (NHL) is sometimes treated with stem cell transplant.

• #11 Non-Hodgkin lymphoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/diagnosis-treatment/drc-20375685

  Non-Hodgkin lymphoma treatment often starts with medicines or radiation therapy. Medicines used for this cancer include chemotherapy, immunotherapy and targeted therapy. […] The treatments your healthcare team chooses for you depend on your lymphoma. Your healthcare team considers the types of cells involved and how quickly the cancer is growing. Your team also considers your overall health and what you prefer. […] If your lymphoma seems to be growing slowly and doesn’t cause symptoms, you might not need treatment right away. Instead, you may have checkups every few months. The checkups help your healthcare team watch your condition and see if your cancer is growing. […] Chemotherapy treats cancer with strong medicines. There are many chemotherapy medicines. Most chemotherapy medicines are given through a vein. Some come in pill form.

• #12 Treating Non-Hodgkin lymphoma (NHL) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin/treatment

  You may have one, or a combination, of the following treatments: chemotherapy with different drugs, targeted therapy and immunotherapies, radiotherapy, stem cell transplant, CAR-T therapy. […] For some people with low-grade lymphoma, the doctor may suggest monitoring the lymphoma with regular tests rather than starting more treatment straight away. This is called watch and wait.

• #13 4 Innovative Non-Hodgkin Lymphoma Treatment Options | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/non-hodgkin-lymphoma/non-hodgkin-lymphoma-treatment.html

  Proton therapy delivers high radiation doses directly to the tumor site, with minimal damage to nearby healthy tissue. […] Immunotherapy for Non-Hodgkin lymphoma may include: Chimeric Antigen Receptor (CAR) T cell therapy, Monoclonal antibodies including rituximab, Biological therapies that develop antibodies to help the body fight the cancer, Immune modulators, such lenalidomide, that modify the environment of the tumor cell and allow the immune system to kill the cancer, Targeted therapies that attack cancer cells by using small molecules to block pathways cells used to survive and multiply, Small molecule treatments. […] If non-Hodgkin lymphoma does not respond to chemotherapy or if it returns, your doctor may recommend a stem cell transplant. […] This approach involves closely monitoring non-Hodgkin lymphoma without active treatment. Sometimes this is appropriate for some patients with low-grade lymphomas.

• #14 Treating Non-Hodgkin lymphoma (NHL) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin/treatment

  Treatment for non-Hodgkin lymphoma (NHL) depends on the type and stage of the lymphoma you have. Chemotherapy is the most common treatment for NHL. […] There are different types of treatment for NHL. You may need just one type of treatment or a combination of treatments. […] The most common treatment for early stage (stage 1 or 2), low-grade NHL is radiotherapy. It is given to the affected lymph nodes and can usually make the lymphoma disappear completely. Some people are cured after radiotherapy alone. […] Treatment aims to control the lymphoma rather than cure it. It is often very successful at shrinking the lymphoma. You will feel well and will not have any symptoms. This is called remission. […] When low-grade advanced NHL causes symptoms, the most common treatments are: chemotherapy, rituximab or a similar targeted and immunotherapy drug, a combination of chemotherapy and a targeted and immunotherapy drug (called chemoimmunotherapy).

• #15 Treating Non-Hodgkin lymphoma (NHL) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin/treatment

  High-grade lymphoma is usually fast-growing and needs to be treated straightaway. The aim is to make the lymphoma disappear completely. This is called complete remission. […] The most commonly used treatments are: chemotherapy and steroids, a combination of chemotherapy and a targeted and immunotherapy drug, such as rituximab (chemoimmunotherapy) and steroids. […] Many people with high-grade NHL are cured. But if the lymphoma does not completely respond to treatment your doctor may talk to you about having more intensive treatment. This may involve high-dose chemotherapy with a stem cell transplant using your own or a donor’s stem cells. […] Treatment can often cure high-grade NHL. But, in some people, the lymphoma comes back. If this happens, it may be possible to have more treatment to try to cure it.

• #16 Medications for Non-Hodgkin Lymphoma | NYU Langone Health

  https://nyulangone.org/conditions/non-hodgkin-lymphoma/treatments/medications-for-non-hodgkin-lymphoma

  Chemotherapy drugs are used to kill cancer cells throughout the body. These medications may be given by mouth or through a vein in an IV infusion. The type of non-Hodgkin lymphoma and the genetic features of the tumor tissue, determined at the time of diagnosis, help your doctors decide which chemotherapy drugs to use, as well as the length and number of treatment cycles. Often, our doctors give chemotherapy a few times each week in several cycles that last three or four weeks each. […] For slow-growing non-Hodgkin lymphoma, our doctors recommend using less aggressive chemotherapy drugs to manage the cancer, whereas a combination may be needed for intermediate or aggressive cancer. […] New targeted therapies, for example, monoclonal antibody medications, are also used in the management of non-Hodgkin lymphoma. These medications are made with antibodies, the immune proteins that recognize substances as foreign and help remove them from the body. Monoclonal antibodies attach to proteins on the surface of non-Hodgkin lymphoma cells, interfering with their ability to function. Because monoclonal antibodies target cancer cells and not healthy tissue, they may cause fewer side effects than chemotherapy. They are usually given through an IV.

• #17 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  High-dose therapy with autologous stem cell rescue (HDT/ASCR) is used as salvage therapy in patients with relapsed or refractory DLBCL. […] Chimeric antigen receptor (CAR) T-cell therapy has emerged as a preferred treatment for patients who do not wish to undergo HDT/ASCR. […] For second-line therapy of patients who do not intend to proceed with HDT/ASCR, the following regimens are listed as preferred by the NCCN. […] Nonchemotherapy options such as ibrutinib or lenalidomide-rituximab may be considered in certain circumstances. […] The US Food and Drug Administration (FDA) recently approved new treatments for patients with relapsed/refractory DLBCL after at least 2 prior lines of therapy, including epcoritamab-bysp (Epkinly) in May 2023 and glofitamab-gxbm (Columvi) in June 2023. […] The preferred first-line treatments for patients with follicular lymphoma include bendamustine+obinutuzumab or rituximab; CHOP+obinutuzumab or rituximab; CVP (cyclophosphamide, vincristine sulfate, prednisone)+obinutuzumab or rituximab; or lenalidomide+rituximab.

• #18 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  High-dose therapy with autologous stem cell rescue (HDT/ASCR) is used as salvage therapy in patients with relapsed or refractory DLBCL. […] Chimeric antigen receptor (CAR) T-cell therapy has emerged as a preferred treatment for patients who do not wish to undergo HDT/ASCR. […] For second-line therapy of patients who do not intend to proceed with HDT/ASCR, the following regimens are listed as preferred by the NCCN. […] Nonchemotherapy options such as ibrutinib or lenalidomide-rituximab may be considered in certain circumstances. […] The US Food and Drug Administration (FDA) recently approved new treatments for patients with relapsed/refractory DLBCL after at least 2 prior lines of therapy, including epcoritamab-bysp (Epkinly) in May 2023 and glofitamab-gxbm (Columvi) in June 2023. […] The preferred first-line treatments for patients with follicular lymphoma include bendamustine+obinutuzumab or rituximab; CHOP+obinutuzumab or rituximab; CVP (cyclophosphamide, vincristine sulfate, prednisone)+obinutuzumab or rituximab; or lenalidomide+rituximab.

• #19 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  High-dose therapy with autologous stem cell rescue (HDT/ASCR) is used as salvage therapy in patients with relapsed or refractory DLBCL. […] Chimeric antigen receptor (CAR) T-cell therapy has emerged as a preferred treatment for patients who do not wish to undergo HDT/ASCR. […] For second-line therapy of patients who do not intend to proceed with HDT/ASCR, the following regimens are listed as preferred by the NCCN. […] Nonchemotherapy options such as ibrutinib or lenalidomide-rituximab may be considered in certain circumstances. […] The US Food and Drug Administration (FDA) recently approved new treatments for patients with relapsed/refractory DLBCL after at least 2 prior lines of therapy, including epcoritamab-bysp (Epkinly) in May 2023 and glofitamab-gxbm (Columvi) in June 2023. […] The preferred first-line treatments for patients with follicular lymphoma include bendamustine+obinutuzumab or rituximab; CHOP+obinutuzumab or rituximab; CVP (cyclophosphamide, vincristine sulfate, prednisone)+obinutuzumab or rituximab; or lenalidomide+rituximab.

• #20 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  High-dose therapy with autologous stem cell rescue (HDT/ASCR) is used as salvage therapy in patients with relapsed or refractory DLBCL. […] Chimeric antigen receptor (CAR) T-cell therapy has emerged as a preferred treatment for patients who do not wish to undergo HDT/ASCR. […] For second-line therapy of patients who do not intend to proceed with HDT/ASCR, the following regimens are listed as preferred by the NCCN. […] Nonchemotherapy options such as ibrutinib or lenalidomide-rituximab may be considered in certain circumstances. […] The US Food and Drug Administration (FDA) recently approved new treatments for patients with relapsed/refractory DLBCL after at least 2 prior lines of therapy, including epcoritamab-bysp (Epkinly) in May 2023 and glofitamab-gxbm (Columvi) in June 2023. […] The preferred first-line treatments for patients with follicular lymphoma include bendamustine+obinutuzumab or rituximab; CHOP+obinutuzumab or rituximab; CVP (cyclophosphamide, vincristine sulfate, prednisone)+obinutuzumab or rituximab; or lenalidomide+rituximab.

• #21 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  High-dose therapy with autologous stem cell rescue (HDT/ASCR) is used as salvage therapy in patients with relapsed or refractory DLBCL. […] Chimeric antigen receptor (CAR) T-cell therapy has emerged as a preferred treatment for patients who do not wish to undergo HDT/ASCR. […] For second-line therapy of patients who do not intend to proceed with HDT/ASCR, the following regimens are listed as preferred by the NCCN. […] Nonchemotherapy options such as ibrutinib or lenalidomide-rituximab may be considered in certain circumstances. […] The US Food and Drug Administration (FDA) recently approved new treatments for patients with relapsed/refractory DLBCL after at least 2 prior lines of therapy, including epcoritamab-bysp (Epkinly) in May 2023 and glofitamab-gxbm (Columvi) in June 2023. […] The preferred first-line treatments for patients with follicular lymphoma include bendamustine+obinutuzumab or rituximab; CHOP+obinutuzumab or rituximab; CVP (cyclophosphamide, vincristine sulfate, prednisone)+obinutuzumab or rituximab; or lenalidomide+rituximab.

• #22 Treating Non-Hodgkin lymphoma (NHL) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin/treatment

  Treatment for non-Hodgkin lymphoma (NHL) depends on the type and stage of the lymphoma you have. Chemotherapy is the most common treatment for NHL. […] There are different types of treatment for NHL. You may need just one type of treatment or a combination of treatments. […] The most common treatment for early stage (stage 1 or 2), low-grade NHL is radiotherapy. It is given to the affected lymph nodes and can usually make the lymphoma disappear completely. Some people are cured after radiotherapy alone. […] Treatment aims to control the lymphoma rather than cure it. It is often very successful at shrinking the lymphoma. You will feel well and will not have any symptoms. This is called remission. […] When low-grade advanced NHL causes symptoms, the most common treatments are: chemotherapy, rituximab or a similar targeted and immunotherapy drug, a combination of chemotherapy and a targeted and immunotherapy drug (called chemoimmunotherapy).

• #23 Non-Hodgkin lymphoma | Causes, Symptoms & Treatments | Cancer Council

  https://www.cancer.org.au/cancer-information/types-of-cancer/non-hodgkin-lymphoma

  Radiation therapy uses x-rays to kill or injure cancer cells and is generally used in early stage (I or II) of non-Hodgkin lymphoma. In more advanced lymphomas, a combination of radiation therapy and chemotherapy is usually used. […] Your doctor may recommend a stem cell transplant if there is a risk of the cancer returning, if the cancer has returned or if you have not responded to other forms of treatment. […] In some cases of non-Hodgkin lymphoma, your medical team may talk to you about palliative care. Palliative care aims to improve your quality of life by alleviating symptoms of cancer without aiming to cure the disease. […] As well as slowing the spread of non-Hodgkin lymphoma, palliative treatment can relieve pain and help to manage other symptoms. Treatment may include chemotherapy, radiotherapy or other drug therapies. […] Depending on your treatment, your treatment team may consist of a number of different health professionals, such as GP (General Practitioner), Haematologist, Radiation oncologist, Medical oncologist, Cancer nurse, and other allied health professionals.

• #24 Non-Hodgkin Lymphoma Treatment – NCI

  https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq

  Treatment of indolent stage I and indolent, contiguous stage II non-Hodgkin lymphoma may include the following: Radiation therapy, Monoclonal antibody therapy (rituximab) and/or chemotherapy, Watchful waiting. […] Treatment of aggressive stage I and aggressive, contiguous stage II non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab) and combination chemotherapy. […] Treatment of aggressive, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab) with combination chemotherapy, Combination chemotherapy. […] Treatment of recurrent non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab or obinutuzumab) with or without chemotherapy, Lenalidomide and rituximab, EZH2 inhibitor therapy (tazemetostat), Radiation therapy as palliative therapy to relieve symptoms and improve quality of life.

• #25 Treatments for non-Hodgkin lymphoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment

  Your healthcare team will create a treatment plan just for you. The plan is based on your health and specific information about the cancer. What you want is also important when planning treatment. When deciding which treatments to offer for non-Hodgkin lymphoma (NHL), your healthcare team will consider: […] When planning treatment, the healthcare will look at if the NHL is an indolent or aggressive type. […] Indolent NHL means that the cancer is growing slowly. Because it grows slowly, some people will only ever need watchful waiting. If other treatments are used, like chemotherapy or targeted therapy, indolent NHLs usually respond well to treatment and can often be controlled for many years. […] Aggressive NHL means that the cancer is growing quickly. An aggressive NHL often causes symptoms soon after it develops, and these symptoms usually need to be treated right away. Aggressive NHLs usually respond well to treatment.

• #26 Treating Non-Hodgkin lymphoma (NHL) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin/treatment

  High-grade lymphoma is usually fast-growing and needs to be treated straightaway. The aim is to make the lymphoma disappear completely. This is called complete remission. […] The most commonly used treatments are: chemotherapy and steroids, a combination of chemotherapy and a targeted and immunotherapy drug, such as rituximab (chemoimmunotherapy) and steroids. […] Many people with high-grade NHL are cured. But if the lymphoma does not completely respond to treatment your doctor may talk to you about having more intensive treatment. This may involve high-dose chemotherapy with a stem cell transplant using your own or a donor’s stem cells. […] Treatment can often cure high-grade NHL. But, in some people, the lymphoma comes back. If this happens, it may be possible to have more treatment to try to cure it.

• #27 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  Aggressive non-Hodgkin lymphoma (NHL) progresses rapidly. Treatment for aggressive B-cell NHL subtypes starts at the time of diagnosis. Patients with fast-growing NHL are frequently treated with chemotherapy that consists of four or more drugs. In most cases, this is the combination therapy called R-CHOP (rituximab [Rituxan], cyclophosphamide [Cytoxan], doxorubicin [hydroxydoxorubicin], Oncovin [vincristine] and prednisone). This intensive, multidrug chemotherapy can be very effective for aggressive lymphoma, and cures have been achieved. Chemotherapy can be supplemented by radiation therapy in select cases, for instance, when large NHL masses are found during the diagnostic and staging process. […] Treatment outcomes depend on how well the patient with AIDS responds to therapy and manages the effects of chemotherapy on blood counts.

• #28 Non-Hodgkin’s Lymphoma | Conditions | UCSF Health

  https://www.ucsfhealth.org/conditions/non-hodgkins-lymphoma

  The most common therapy for non-Hodgkin’s lymphoma is called R-CHOP and consists of four different chemotherapy medications plus a type of immunotherapy called rituximab, which specifically targets some lymphoma cells. […] Radiation therapy, also called radiotherapy, is the use of high-energy rays to kill cancer cells. Treatment with radiation may be given alone or with chemotherapy. […] At UCSF Medical Center, stem cell transplantation, also called bone marrow transplantation, is offered to all patients with recurrent non-Hodgkin’s lymphoma. […] Biological therapy, also called immunotherapy, is a form of treatment that uses the body’s immune system, either directly or indirectly, to fight cancer or to lessen the side effects that can be caused by some cancer treatments.

• #29 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  Aggressive non-Hodgkin lymphoma (NHL) progresses rapidly. Treatment for aggressive B-cell NHL subtypes starts at the time of diagnosis. Patients with fast-growing NHL are frequently treated with chemotherapy that consists of four or more drugs. In most cases, this is the combination therapy called R-CHOP (rituximab [Rituxan], cyclophosphamide [Cytoxan], doxorubicin [hydroxydoxorubicin], Oncovin [vincristine] and prednisone). This intensive, multidrug chemotherapy can be very effective for aggressive lymphoma, and cures have been achieved. Chemotherapy can be supplemented by radiation therapy in select cases, for instance, when large NHL masses are found during the diagnostic and staging process. […] Treatment outcomes depend on how well the patient with AIDS responds to therapy and manages the effects of chemotherapy on blood counts.

• #30 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  The following treatment recommendations established by the National Comprehensive Cancer Network (NCCN) offer guidance on induction therapy, maintenance therapy, and treatment for relapsed or refractory disease for the most common types of B-cell lymphoma. […] Cure is possible for a substantial number of patients with Burkitt lymphoma by using dose-intensive multiagent chemotherapy regimens. However, this type of cancer grows very quickly, so immediate treatment is important. More than half of people with Burkitt lymphoma can be cured with intensive chemotherapy. […] Treatment recommendations from the NCCN involve chemotherapy and central nervous system prophylaxis with intrathecal chemotherapy. […] First-line treatment recommendations for patients with stage I to II DLBCL (excluding stage II with extensive mesenteric disease) include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or pola-R-CHP (polatuzumab vedotin-piiq, rituximab, cyclophosphamide, doxorubicin, prednisone).

• #31 Non-Hodgkin lymphoma – Wikipedia

  https://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma

  Treatment depends on whether the lymphoma is slow or fast growing and if it is in one area or many areas. Treatments may include chemotherapy, radiation, immunotherapy, targeted therapy, stem-cell transplantation, surgery, or watchful waiting. […] The traditional treatment of NHL includes chemotherapy, radiotherapy, and stem-cell transplants. There have also been developments in immunotherapy used in the treatment of NHL. […] The most common chemotherapy used for B-cell non-Hodgkin lymphoma is R-CHOP, which is a regimen of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab. […] R-CHP with polatuzumab vedotin, an antibody-drug conjugate, was included as a category 1 preferred regimen for first-line DLBCL by the National Comprehensive Cancer Network in 2023. […] If participants receive stem-cell transplants, they can develop a graft-versus-host disease. […] Platelet transfusions may be necessary for those who receive chemotherapy or undergo a stem cell transplantation due to the higher risk for bleeding.

• #32 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  Doctors typically use highly aggressive chemotherapy that often require admission to the hospital to treat this subtype of NHL. Commonly used regimens include: CODOX-M/IVAC (cyclophosphamide, vincristine [Oncovin], doxorubicin and high-dose methotrexate) alternating with IVAC (ifosfamide, etoposide and highdose cytarabine). […] Studies report that BL is curable in a significant group of patients when treated with high-dose, multidrug chemotherapy regimens that include central nervous system (CNS) prophylaxis. About 60 to 90 percent of children and young adults with the disease achieve durable remissions if treated timely and appropriately. […] Standard treatment may include chemotherapy that includes intrathecal methotrexate, corticosteroid drugs and/or radiation therapy. Immunotherapy and high-dose chemotherapy with stem cell transplantation are being studied in clinical trials.

• #33 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  Doctors typically use highly aggressive chemotherapy that often require admission to the hospital to treat this subtype of NHL. Commonly used regimens include: CODOX-M/IVAC (cyclophosphamide, vincristine [Oncovin], doxorubicin and high-dose methotrexate) alternating with IVAC (ifosfamide, etoposide and highdose cytarabine). […] Studies report that BL is curable in a significant group of patients when treated with high-dose, multidrug chemotherapy regimens that include central nervous system (CNS) prophylaxis. About 60 to 90 percent of children and young adults with the disease achieve durable remissions if treated timely and appropriately. […] Standard treatment may include chemotherapy that includes intrathecal methotrexate, corticosteroid drugs and/or radiation therapy. Immunotherapy and high-dose chemotherapy with stem cell transplantation are being studied in clinical trials.

• #34 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  Treatments for previously untreated patients include: R-CHOP (rituximab [Rituxan], cyclophosphamide [Cytoxan], doxorubicin [hydroxydoxorubicin], Oncovin [vincristine] and prednisone). […] The standard treatment is a combination chemotherapy regimen, either with or without an autologous stem cell transplant. […] For most newly diagnosed cases of PTCL, the initial treatment is usually combination chemotherapy. Clinical trials are underway to study the efficacy and safety of potential new drugs and drug combinations to treat PTCL. […] Patients with PMBCL often need more intensive treatment. There are two standard combination regimens: R-EPOCH and R-CHOP. The R-EPOCH regimen is being used more often as a treatment for PMBCL, as there is less need for radiation therapy with this regimen. Treatment for people whose disease is refractory to treatment or has relapsed includes the monoclonal antibody pembrolizumab (Keytruda), and the CAR T-cell therapy products axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (Breyanzi).

• #35 logo–sylvester

  https://umiamihealth.org/en/sylvester-comprehensive-cancer-center/treatments-and-services/hematologic-(blood)-cancers-/non-hodgkin-lymphoma

  Immunotherapy: This treatment makes use of substances made to simulate the protective actions of your immune system. These drugs help your immune system to fight the lymphoma. […] Targeted Therapy: This treatment uses medicines to attack parts of cancer cells that make them unique from healthy cells. […] Radiation Therapy: Radiation therapy is used to consolidate gains made by systemic treatments, especially in areas where there was a large volume of disease originally or where disease persists after chemotherapy. […] Stem Cell Transplant: Stem cells can come from a donor (allogeneic transplant) or your own body (autologous transplant). This process occurs before you undergo high dose chemotherapy or radiation therapy to kill off cancer cells. […] In rare cases, a surgeon may take out an organ, such as your spleen, if it has lymphoma.

• #36 Non-Hodgkin Lymphoma (NHL) Treatment & Management: Approach Considerations, Management of Indolent NHL, Management of Aggressive NHL

  https://emedicine.medscape.com/article/203399-treatment

  Randomized trials have shown that adding rituximab to chemotherapy regimens results in higher response rates, longer time to progression, and longer survival than chemotherapy. […] Maintenance therapy with rituximab after induction chemotherapy has been reported to prolong progression-free survival (PFS) in comparison with observation alone in patients with indolent lymphoma. […] In patients with indolent NHL that is refractory to rituximab, obinutuzumab plus bendamustine followed by obinutuzumab maintenance has improved efficacy over bendamustine monotherapy, with manageable toxicity. […] High-dose chemotherapy plus stem-cell transplantation is the treatment of choice for patients who have recurrent aggressive lymphomas. […] In 2019, polatuzumab vedotin, a CD79b-directed antibody-drug conjugate, gained accelerated approval from the FDA for use in combination with bendamustine and a rituximab product for adults with relapsed or recurrent DLBCL who have received at least 2 prior therapies and are not candidates for transplantation.

• #37 Non-Hodgkin Lymphoma – Treatment Options – Messino Cancer Centers

  https://messinocancercenters.com/resource/non-hodgkin-lymphoma/non-hodgkin-lymphoma-treatment-options/

  Radiation treatment for NHL is usually external-beam radiation therapy, which is radiation given from a machine outside the body. […] A bone marrow transplant is a medical procedure in which bone marrow or peripheral blood cells containing highly specialized cells, called hematopoietic stem cells, are used as part of a treatment plan. […] Transplantation is considered an aggressive treatment. It is generally used only for people with NHL whose disease is progressive or recurrent. […] For some NHL subtypes, such as mantle cell lymphoma and some T-cell lymphomas, doctors may recommend transplantation as part of the initial treatment plan to prevent recurrence. […] Treatment options for refractory NHL depend on 4 factors: Where the cancer is, The lymphoma subtype, The type of treatment given before, The patients overall health.

• #38 Non-Hodgkin lymphoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/diagnosis-treatment/drc-20375685

  For many types of non-Hodgkin lymphoma, chemotherapy is the first treatment. Sometimes it’s combined with targeted therapy. […] Immunotherapy for cancer is a treatment with medicine that helps the body’s immune system kill cancer cells. The immune system fights off diseases by attacking germs and other cells that shouldn’t be in the body. Cancer cells survive by hiding from the immune system. Immunotherapy helps the immune system cells find and kill the cancer cells. […] People with certain types of non-Hodgkin lymphoma may have immunotherapy if other treatments haven’t helped. […] Targeted therapy for cancer is a treatment that uses medicines that attack specific chemicals in the cancer cells. By blocking these chemicals, targeted treatments can cause cancer cells to die. […] For non-Hodgkin lymphoma, targeted therapy may be used alone. But more often, it’s combined with chemotherapy. This mix may be your first treatment. It can be your second treatment if your lymphoma comes back.

• #39 Immunotherapy for non-Hodgkin lymphoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment/immunotherapy

  Immunotherapy helps to strengthen or restore the immune system’s ability to fight cancer. This works to kill cancer cells and stop cancer cells from growing and spreading. […] Immunotherapy is sometimes used to treat non-Hodgkin lymphoma (NHL). If you have immunotherapy, your healthcare team will use what they know about the cancer and about your health to plan the drugs, doses and schedules. […] Immunotherapy may be the only treatment you have or it may be used along with other treatments. You may have immunotherapy to: treat NHL that expresses certain proteins, treat NHL that comes back or doesn’t respond to other treatments, control symptoms of NHL. […] Different types of immunotherapy are used for NHL. These include: immune checkpoint inhibitors, CAR T-cell therapy, bispecific antibodies.

• #40 Non-Hodgkin Lymphoma – Treatment Options – Messino Cancer Centers

  https://messinocancercenters.com/resource/non-hodgkin-lymphoma/non-hodgkin-lymphoma-treatment-options/

  A chemotherapy regimen, or schedule, usually consists of a specific number of cycles given over a set period of time. A patient may receive 1 drug at a time or a combination of different drugs given at the same time. The stage and type of NHL determines which chemotherapy is used. […] The most common chemotherapy combination for the first treatment of aggressive NHL is called CHOP and contains 4 medications: Cyclophosphamide, Doxorubicin, Prednisone, Vincristine. […] For patients with B-cell lymphoma, adding an anti-CD20 monoclonal antibody, such as rituximab or obinutuzumab, to CHOP works better than using CHOP alone. […] Targeted therapy is a treatment that targets the cancers specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells while limiting damage to healthy cells.

• #41 Non-Hodgkin Lymphoma (NHL) Treatment & Management: Approach Considerations, Management of Indolent NHL, Management of Aggressive NHL

  https://emedicine.medscape.com/article/203399-treatment

  Randomized trials have shown that adding rituximab to chemotherapy regimens results in higher response rates, longer time to progression, and longer survival than chemotherapy. […] Maintenance therapy with rituximab after induction chemotherapy has been reported to prolong progression-free survival (PFS) in comparison with observation alone in patients with indolent lymphoma. […] In patients with indolent NHL that is refractory to rituximab, obinutuzumab plus bendamustine followed by obinutuzumab maintenance has improved efficacy over bendamustine monotherapy, with manageable toxicity. […] High-dose chemotherapy plus stem-cell transplantation is the treatment of choice for patients who have recurrent aggressive lymphomas. […] In 2019, polatuzumab vedotin, a CD79b-directed antibody-drug conjugate, gained accelerated approval from the FDA for use in combination with bendamustine and a rituximab product for adults with relapsed or recurrent DLBCL who have received at least 2 prior therapies and are not candidates for transplantation.

• #42 Immunotherapy for non-Hodgkin lymphoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment/immunotherapy

  The immunotherapy drugs used to treat NHL may not be covered by all provincial or territorial health plans. […] Immune checkpoint inhibitors are drugs that block the checkpoint proteins so immune system cells, such as T cells, can attack and kill the lymphoma cells. […] Pembrolizumab (Keytruda) is an immune checkpoint inhibitor that may be used to treat primary mediastinal large B-cell lymphoma (PMBCL) that doesn’t respond to treatment (called refractory disease) or comes back (relapses) after 2 different types of chemotherapy or targeted therapy. […] CAR T-cell therapy is a very complex treatment. It involves removing some T cells from your blood, making small changes to them in the lab and then giving them back to you. […] The following CAR T-cell therapies may be used to treat NHL.

• #43 Immunotherapy for non-Hodgkin lymphoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment/immunotherapy

  The immunotherapy drugs used to treat NHL may not be covered by all provincial or territorial health plans. […] Immune checkpoint inhibitors are drugs that block the checkpoint proteins so immune system cells, such as T cells, can attack and kill the lymphoma cells. […] Pembrolizumab (Keytruda) is an immune checkpoint inhibitor that may be used to treat primary mediastinal large B-cell lymphoma (PMBCL) that doesn’t respond to treatment (called refractory disease) or comes back (relapses) after 2 different types of chemotherapy or targeted therapy. […] CAR T-cell therapy is a very complex treatment. It involves removing some T cells from your blood, making small changes to them in the lab and then giving them back to you. […] The following CAR T-cell therapies may be used to treat NHL.

• #44 Non-Hodgkin lymphoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/diagnosis-treatment/drc-20375685

  Chimeric antigen receptor T cell therapy, also called CAR-T cell therapy, trains the immune system cells to fight non-Hodgkin lymphoma. This treatment begins with removing some white blood cells, including T cells, from the blood. […] A bone marrow transplant, also called a bone marrow stem cell transplant, involves putting healthy bone marrow stem cells into the body. These cells replace cells hurt by chemotherapy and other treatments. People with non-Hodgkin lymphoma may have a bone marrow transplant if other treatments haven’t helped. […] Radiation therapy treats cancer with powerful energy beams. The energy can come from X-rays, protons or other sources. During radiation therapy, you lie on a table while a machine moves around you. The machine directs radiation to precise points on your body.

• #45 Immunotherapy for non-Hodgkin lymphoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment/immunotherapy

  The immunotherapy drugs used to treat NHL may not be covered by all provincial or territorial health plans. […] Immune checkpoint inhibitors are drugs that block the checkpoint proteins so immune system cells, such as T cells, can attack and kill the lymphoma cells. […] Pembrolizumab (Keytruda) is an immune checkpoint inhibitor that may be used to treat primary mediastinal large B-cell lymphoma (PMBCL) that doesn’t respond to treatment (called refractory disease) or comes back (relapses) after 2 different types of chemotherapy or targeted therapy. […] CAR T-cell therapy is a very complex treatment. It involves removing some T cells from your blood, making small changes to them in the lab and then giving them back to you. […] The following CAR T-cell therapies may be used to treat NHL.

• #46 Lymphoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/lymphoma/diagnosis-treatment/drc-20352642

  Targeted therapy for cancer is a treatment that uses medicines that attack specific chemicals in the cancer cells. By blocking these chemicals, targeted treatments can cause cancer cells to die. Your lymphoma cells might be tested to see if targeted therapy will help you. […] Radiation therapy treats cancer with powerful energy beams. The energy comes from X-rays, protons or other sources. During radiation therapy, you lie on a table while a machine moves around you. The machine directs radiation to precise points in your body. […] Chimeric antigen receptor (CAR)-T cell therapy, also called CAR-T cell therapy, trains your immune system cells to fight lymphoma. This treatment begins with removing some white blood cells, including T cells, from your blood. The cells are sent to a lab. In the lab, the cells are treated to recognize the lymphoma cells. The cells are then put back into your body. They then can find and destroy the lymphoma cells.

• #47 Non-Hodgkin Lymphoma (NHL) Treatment & Management: Approach Considerations, Management of Indolent NHL, Management of Aggressive NHL

  https://emedicine.medscape.com/article/203399-treatment

  Chimeric antigen receptor (CAR) T-cell therapy is approved for use in adult patients with relapsed or refractory large B-cell lymphoma, after two or more lines of systemic therapy. […] The following CAR T-cell therapies have FDA approval: Axicabtagene ciloleucel (Yescarta), Tisagenlecleucel (Kymriah), and Lisocabtagene maraleucel (Breyanzi).

• #48 Immunotherapy for non-Hodgkin lymphoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment/immunotherapy

  Bispecific antibodies are a new type of immunotherapy designed to attach to 2 different targets an immune cell and a cancer cell. Bispecific antibodies bring the 2 cells together to help the body’s immune system attack the lymphoma cells. […] Epcoritamab (Epkinly) can be used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an indolent (slow-growing) lymphoma that transformed into DLBCL, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma or grade 3B follicular lymphoma. […] Glofitamab (Columvi) can be used to treat relapsed or refractory DLBCL, DLBCL that develops from follicular lymphoma or DLBCL that develops from primary mediastinal B-cell lymphoma.

• #49 Immunotherapy for non-Hodgkin lymphoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/treatment/immunotherapy

  Bispecific antibodies are a new type of immunotherapy designed to attach to 2 different targets an immune cell and a cancer cell. Bispecific antibodies bring the 2 cells together to help the body’s immune system attack the lymphoma cells. […] Epcoritamab (Epkinly) can be used to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an indolent (slow-growing) lymphoma that transformed into DLBCL, high-grade B-cell lymphoma, primary mediastinal B-cell lymphoma or grade 3B follicular lymphoma. […] Glofitamab (Columvi) can be used to treat relapsed or refractory DLBCL, DLBCL that develops from follicular lymphoma or DLBCL that develops from primary mediastinal B-cell lymphoma.

• #50 Non-Hodgkin lymphoma – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/non-hodgkins-lymphoma/diagnosis-treatment/drc-20375685

  For many types of non-Hodgkin lymphoma, chemotherapy is the first treatment. Sometimes it’s combined with targeted therapy. […] Immunotherapy for cancer is a treatment with medicine that helps the body’s immune system kill cancer cells. The immune system fights off diseases by attacking germs and other cells that shouldn’t be in the body. Cancer cells survive by hiding from the immune system. Immunotherapy helps the immune system cells find and kill the cancer cells. […] People with certain types of non-Hodgkin lymphoma may have immunotherapy if other treatments haven’t helped. […] Targeted therapy for cancer is a treatment that uses medicines that attack specific chemicals in the cancer cells. By blocking these chemicals, targeted treatments can cause cancer cells to die. […] For non-Hodgkin lymphoma, targeted therapy may be used alone. But more often, it’s combined with chemotherapy. This mix may be your first treatment. It can be your second treatment if your lymphoma comes back.

• #51 Treatment Options for Lymphoma | Lymphoma Research Foundation

  https://lymphoma.org/understanding-lymphoma/treatment-planning-and-options/treatments/

  Clinical trials are appropriate for patients at all stages of disease. […] The term immunotherapy (also called immune-oncology) refers to treatments that interact with the immune system. […] Radiation therapy (also called radiotherapy) uses high-energy x-rays to kill cancer cells and shrink tumors. […] The ability to transplant stem cells allows physicians to use higher doses of chemotherapy to treat the cancer than the body would normally tolerate, increasing the probability of killing cancer cells. […] Most types of targeted therapy help treat lymphoma by interfering with specific proteins that help tumors grow and spread throughout the body.

• #52 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  High-dose therapy with autologous stem cell rescue (HDT/ASCR) is used as salvage therapy in patients with relapsed or refractory DLBCL. […] Chimeric antigen receptor (CAR) T-cell therapy has emerged as a preferred treatment for patients who do not wish to undergo HDT/ASCR. […] For second-line therapy of patients who do not intend to proceed with HDT/ASCR, the following regimens are listed as preferred by the NCCN. […] Nonchemotherapy options such as ibrutinib or lenalidomide-rituximab may be considered in certain circumstances. […] The US Food and Drug Administration (FDA) recently approved new treatments for patients with relapsed/refractory DLBCL after at least 2 prior lines of therapy, including epcoritamab-bysp (Epkinly) in May 2023 and glofitamab-gxbm (Columvi) in June 2023. […] The preferred first-line treatments for patients with follicular lymphoma include bendamustine+obinutuzumab or rituximab; CHOP+obinutuzumab or rituximab; CVP (cyclophosphamide, vincristine sulfate, prednisone)+obinutuzumab or rituximab; or lenalidomide+rituximab.

• #53 Non-Hodgkin’s Lymphoma Treatment: Combination Therapy

  https://www.webmd.com/cancer/lymphoma/non-hodgkins-multiple-treatments

  R-CHOP causes side effects for most people. Some of these, like a high fever and very low white blood cell count, are life-threatening. […] This type of immunotherapy combines a monoclonal antibody like rituximab with a single chemo drug. […] One example is a drug called brentuximab vedotin (Adcetris). […] This treatment works like antibody-drug conjugates, but the antibody is attached to a radioactive molecule. […] Your doctor may prescribe a medicine called ibritumomab tiuxetan (Zevalin) if you have follicular cell lymphoma that comes back or isn’t helped by other treatments. Some of the most serious side effects of radioimmunotherapy are very low blood counts and the chance you’ll get another kind of cancer.

• #54 Non-Hodgkin Lymphoma (NHL) Treatment & Management: Approach Considerations, Management of Indolent NHL, Management of Aggressive NHL

  https://emedicine.medscape.com/article/203399-treatment

  Randomized trials have shown that adding rituximab to chemotherapy regimens results in higher response rates, longer time to progression, and longer survival than chemotherapy. […] Maintenance therapy with rituximab after induction chemotherapy has been reported to prolong progression-free survival (PFS) in comparison with observation alone in patients with indolent lymphoma. […] In patients with indolent NHL that is refractory to rituximab, obinutuzumab plus bendamustine followed by obinutuzumab maintenance has improved efficacy over bendamustine monotherapy, with manageable toxicity. […] High-dose chemotherapy plus stem-cell transplantation is the treatment of choice for patients who have recurrent aggressive lymphomas. […] In 2019, polatuzumab vedotin, a CD79b-directed antibody-drug conjugate, gained accelerated approval from the FDA for use in combination with bendamustine and a rituximab product for adults with relapsed or recurrent DLBCL who have received at least 2 prior therapies and are not candidates for transplantation.

• #55 Treatment Options for Non-Hodgkin Lymphoma :: MN Oncology

  https://mnoncology.com/cancers-and-blood-disorders/blood-cancers/non-hodgkin-lymphoma/treatment-options-non-hodgkin-lymphoma

  People with certain types of non-Hodgkin lymphoma may have biological therapy. This type of treatment helps the immune system fight cancer. […] Monoclonal antibodies are the type of biological therapy used for lymphoma. They are proteins made in the lab that can bind to cancer cells. They help the immune system kill lymphoma cells. […] Radiation therapy (also called radiotherapy) uses high-energy rays to kill lymphoma cells. It can shrink tumors and help control pain. […] Two types of radiation therapy are used for people with lymphoma: External radiation: A large machine aims the rays at the part of the body where lymphoma cells have collected. […] Systemic radiation: Some people with lymphoma receive an injection of radioactive material that travels throughout the body. The radioactive material is bound to monoclonal antibodies that seek out lymphoma cells. The radiation destroys the lymphoma cells.

• #56 Non-Hodgkin’s Lymphoma Treatment: Combination Therapy

  https://www.webmd.com/cancer/lymphoma/non-hodgkins-multiple-treatments

  R-CHOP causes side effects for most people. Some of these, like a high fever and very low white blood cell count, are life-threatening. […] This type of immunotherapy combines a monoclonal antibody like rituximab with a single chemo drug. […] One example is a drug called brentuximab vedotin (Adcetris). […] This treatment works like antibody-drug conjugates, but the antibody is attached to a radioactive molecule. […] Your doctor may prescribe a medicine called ibritumomab tiuxetan (Zevalin) if you have follicular cell lymphoma that comes back or isn’t helped by other treatments. Some of the most serious side effects of radioimmunotherapy are very low blood counts and the chance you’ll get another kind of cancer.

• #57 4 Innovative Non-Hodgkin Lymphoma Treatment Options | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/non-hodgkin-lymphoma/non-hodgkin-lymphoma-treatment.html

  Proton therapy delivers high radiation doses directly to the tumor site, with minimal damage to nearby healthy tissue. […] Immunotherapy for Non-Hodgkin lymphoma may include: Chimeric Antigen Receptor (CAR) T cell therapy, Monoclonal antibodies including rituximab, Biological therapies that develop antibodies to help the body fight the cancer, Immune modulators, such lenalidomide, that modify the environment of the tumor cell and allow the immune system to kill the cancer, Targeted therapies that attack cancer cells by using small molecules to block pathways cells used to survive and multiply, Small molecule treatments. […] If non-Hodgkin lymphoma does not respond to chemotherapy or if it returns, your doctor may recommend a stem cell transplant. […] This approach involves closely monitoring non-Hodgkin lymphoma without active treatment. Sometimes this is appropriate for some patients with low-grade lymphomas.

• #58 Non-Hodgkin Lymphoma Treatment – NCI

  https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq

  Treatment of indolent stage I and indolent, contiguous stage II non-Hodgkin lymphoma may include the following: Radiation therapy, Monoclonal antibody therapy (rituximab) and/or chemotherapy, Watchful waiting. […] Treatment of aggressive stage I and aggressive, contiguous stage II non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab) and combination chemotherapy. […] Treatment of aggressive, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab) with combination chemotherapy, Combination chemotherapy. […] Treatment of recurrent non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab or obinutuzumab) with or without chemotherapy, Lenalidomide and rituximab, EZH2 inhibitor therapy (tazemetostat), Radiation therapy as palliative therapy to relieve symptoms and improve quality of life.

• #59 Non-Hodgkin Lymphoma – Treatment Options – Messino Cancer Centers

  https://messinocancercenters.com/resource/non-hodgkin-lymphoma/non-hodgkin-lymphoma-treatment-options/

  Radiation treatment for NHL is usually external-beam radiation therapy, which is radiation given from a machine outside the body. […] A bone marrow transplant is a medical procedure in which bone marrow or peripheral blood cells containing highly specialized cells, called hematopoietic stem cells, are used as part of a treatment plan. […] Transplantation is considered an aggressive treatment. It is generally used only for people with NHL whose disease is progressive or recurrent. […] For some NHL subtypes, such as mantle cell lymphoma and some T-cell lymphomas, doctors may recommend transplantation as part of the initial treatment plan to prevent recurrence. […] Treatment options for refractory NHL depend on 4 factors: Where the cancer is, The lymphoma subtype, The type of treatment given before, The patients overall health.

• #60 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  Refractory non-Hodgkin lymphoma (NHL) is NHL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same. […] Most patients with relapsed or refractory NHL receive second-line therapy (treatment other than the type used the first time around), sometimes followed by stem cell transplantation. Additional treatments for relapsed or refractory lymphomas may be available through a clinical trial. […] High-dose chemotherapy and an autologous stem cell transplant (ASCT) may be used to treat patients whose disease has relapsed after disease remission, but only a minority of patients achieve long-term remissions with this therapy. Allogeneic stem cell transplantation remains a potential cure for relapsed DLBCL, but some patients may not qualify for a transplant due to advanced age or the presence of other medical conditions. The efficacy of reduced-intensity transplantation is being evaluated in clinical trials.

• #61 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  Autologous stem cell transplantation remains a key component of the standard medical care for patients with aggressive forms of non-Hodgkin lymphoma (NHL). For indolent lymphomas, autologous stem cell transplantation is primarily used to treat patients with relapsed NHL. Allogeneic transplantation may be considered in the treatment of indolent forms of NHL, particularly for younger patients whose disease behaves more aggressively or has high-risk features. […] Stem cell transplantation can cause serious side effects that can be life threatening, so it may not be a treatment option for all NHL patients. The risks and benefits of transplantation must always be considered when making treatment decisions.

• #62 Non-Hodgkin Lymphoma Treatment – NYOH

  https://newyorkoncology.com/non-hodgkin-lymphoma/treatment-options

  Chemotherapy is given in cycles. You have a treatment period followed by a rest period. The length of the rest period and the number of treatment cycles depend on the stage of your disease and on the anticancer drugs used. […] People with certain types of non-Hodgkin lymphoma may have biological therapy. This type of treatment of lymphoma helps the immune system fight cancer. […] Monoclonal antibodies are the type of biological therapy used for lymphoma. They are proteins made in the lab that can bind to cancer cells. They help the immune system kill lymphoma cells. […] Radiation therapy (also called radiotherapy) uses high-energy rays to kill lymphoma cells. It can shrink tumors and help control pain. […] If lymphoma returns after treatment, you may receive bone marrow transplant. A transplant of your own blood-forming cells allows you to receive high doses of chemotherapy, radiation therapy, or both. The high doses destroy both lymphoma cells and healthy blood cells in the bone marrow.

• #63 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  Autologous stem cell transplantation remains a key component of the standard medical care for patients with aggressive forms of non-Hodgkin lymphoma (NHL). For indolent lymphomas, autologous stem cell transplantation is primarily used to treat patients with relapsed NHL. Allogeneic transplantation may be considered in the treatment of indolent forms of NHL, particularly for younger patients whose disease behaves more aggressively or has high-risk features. […] Stem cell transplantation can cause serious side effects that can be life threatening, so it may not be a treatment option for all NHL patients. The risks and benefits of transplantation must always be considered when making treatment decisions.

• #64 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  Refractory non-Hodgkin lymphoma (NHL) is NHL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same. […] Most patients with relapsed or refractory NHL receive second-line therapy (treatment other than the type used the first time around), sometimes followed by stem cell transplantation. Additional treatments for relapsed or refractory lymphomas may be available through a clinical trial. […] High-dose chemotherapy and an autologous stem cell transplant (ASCT) may be used to treat patients whose disease has relapsed after disease remission, but only a minority of patients achieve long-term remissions with this therapy. Allogeneic stem cell transplantation remains a potential cure for relapsed DLBCL, but some patients may not qualify for a transplant due to advanced age or the presence of other medical conditions. The efficacy of reduced-intensity transplantation is being evaluated in clinical trials.

• #65 Treating Non-Hodgkin lymphoma (NHL) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin/treatment

  High-grade lymphoma is usually fast-growing and needs to be treated straightaway. The aim is to make the lymphoma disappear completely. This is called complete remission. […] The most commonly used treatments are: chemotherapy and steroids, a combination of chemotherapy and a targeted and immunotherapy drug, such as rituximab (chemoimmunotherapy) and steroids. […] Many people with high-grade NHL are cured. But if the lymphoma does not completely respond to treatment your doctor may talk to you about having more intensive treatment. This may involve high-dose chemotherapy with a stem cell transplant using your own or a donor’s stem cells. […] Treatment can often cure high-grade NHL. But, in some people, the lymphoma comes back. If this happens, it may be possible to have more treatment to try to cure it.

• #66 Treatment for non Hodgkin lymphoma | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/non-hodgkin-lymphoma/treatment

  A stem cell transplant allows you to have high doses of chemotherapy. You then have new stem cells which go into the bone marrow so you can start making blood cells again. […] CAR T-cell therapy is a type of immunotherapy. It is also called adoptive cell transfer. It’s a possible treatment for some children and adults with leukaemia. It is also a treatment for some adults with lymphoma. […] Surgery isnt a common treatment for NHL. You might have surgery to remove your spleen for a rare type of NHL called splenic marginal zone lymphoma. […] After your treatment, you have regular follow up appointments. These are to check how you are and see whether you have any problems or worries. […] NHL that does not respond to treatment is called refractory lymphoma. NHL that comes back after treatment is called relapsed disease.

• #67 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  Refractory non-Hodgkin lymphoma (NHL) is NHL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same. […] Most patients with relapsed or refractory NHL receive second-line therapy (treatment other than the type used the first time around), sometimes followed by stem cell transplantation. Additional treatments for relapsed or refractory lymphomas may be available through a clinical trial. […] High-dose chemotherapy and an autologous stem cell transplant (ASCT) may be used to treat patients whose disease has relapsed after disease remission, but only a minority of patients achieve long-term remissions with this therapy. Allogeneic stem cell transplantation remains a potential cure for relapsed DLBCL, but some patients may not qualify for a transplant due to advanced age or the presence of other medical conditions. The efficacy of reduced-intensity transplantation is being evaluated in clinical trials.

• #68 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  Refractory non-Hodgkin lymphoma (NHL) is NHL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same. […] Most patients with relapsed or refractory NHL receive second-line therapy (treatment other than the type used the first time around), sometimes followed by stem cell transplantation. Additional treatments for relapsed or refractory lymphomas may be available through a clinical trial. […] High-dose chemotherapy and an autologous stem cell transplant (ASCT) may be used to treat patients whose disease has relapsed after disease remission, but only a minority of patients achieve long-term remissions with this therapy. Allogeneic stem cell transplantation remains a potential cure for relapsed DLBCL, but some patients may not qualify for a transplant due to advanced age or the presence of other medical conditions. The efficacy of reduced-intensity transplantation is being evaluated in clinical trials.

• #69 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  Refractory non-Hodgkin lymphoma (NHL) is NHL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same. […] Most patients with relapsed or refractory NHL receive second-line therapy (treatment other than the type used the first time around), sometimes followed by stem cell transplantation. Additional treatments for relapsed or refractory lymphomas may be available through a clinical trial. […] High-dose chemotherapy and an autologous stem cell transplant (ASCT) may be used to treat patients whose disease has relapsed after disease remission, but only a minority of patients achieve long-term remissions with this therapy. Allogeneic stem cell transplantation remains a potential cure for relapsed DLBCL, but some patients may not qualify for a transplant due to advanced age or the presence of other medical conditions. The efficacy of reduced-intensity transplantation is being evaluated in clinical trials.

• #70 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/relapsed-and-refractory

  Refractory non-Hodgkin lymphoma (NHL) is NHL that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same. […] Most patients with relapsed or refractory NHL receive second-line therapy (treatment other than the type used the first time around), sometimes followed by stem cell transplantation. Additional treatments for relapsed or refractory lymphomas may be available through a clinical trial. […] High-dose chemotherapy and an autologous stem cell transplant (ASCT) may be used to treat patients whose disease has relapsed after disease remission, but only a minority of patients achieve long-term remissions with this therapy. Allogeneic stem cell transplantation remains a potential cure for relapsed DLBCL, but some patients may not qualify for a transplant due to advanced age or the presence of other medical conditions. The efficacy of reduced-intensity transplantation is being evaluated in clinical trials.

• #71 Non-Hodgkin Lymphoma (NHL) Treatment & Management: Approach Considerations, Management of Indolent NHL, Management of Aggressive NHL

  https://emedicine.medscape.com/article/203399-treatment

  Randomized trials have shown that adding rituximab to chemotherapy regimens results in higher response rates, longer time to progression, and longer survival than chemotherapy. […] Maintenance therapy with rituximab after induction chemotherapy has been reported to prolong progression-free survival (PFS) in comparison with observation alone in patients with indolent lymphoma. […] In patients with indolent NHL that is refractory to rituximab, obinutuzumab plus bendamustine followed by obinutuzumab maintenance has improved efficacy over bendamustine monotherapy, with manageable toxicity. […] High-dose chemotherapy plus stem-cell transplantation is the treatment of choice for patients who have recurrent aggressive lymphomas. […] In 2019, polatuzumab vedotin, a CD79b-directed antibody-drug conjugate, gained accelerated approval from the FDA for use in combination with bendamustine and a rituximab product for adults with relapsed or recurrent DLBCL who have received at least 2 prior therapies and are not candidates for transplantation.

• #72 Non-Hodgkin Lymphoma (NHL) Treatment & Management: Approach Considerations, Management of Indolent NHL, Management of Aggressive NHL

  https://emedicine.medscape.com/article/203399-treatment

  Chimeric antigen receptor (CAR) T-cell therapy is approved for use in adult patients with relapsed or refractory large B-cell lymphoma, after two or more lines of systemic therapy. […] The following CAR T-cell therapies have FDA approval: Axicabtagene ciloleucel (Yescarta), Tisagenlecleucel (Kymriah), and Lisocabtagene maraleucel (Breyanzi).

• #73 Non-Hodgkin Lymphoma | UH Seidman Cancer Center | University Hospitals | University Hospitals

  https://www.uhhospitals.org/services/cancer-services/hematologic-malignancy/lymphoma/non-hodgkin-lymphoma

  In immunotherapy, certain parts of your own immune system are harnessed to fight cancer. One such therapy is CAR T-cell therapy, which is FDA-approved to treat relapsed and treatment-resistant non-Hodgkin lymphoma in adults. […] Radiation therapy is typically used in the early stage of NHL to alleviate symptoms. For more advanced lymphomas and certain aggressive lymphomas, radiation therapy and chemotherapy may be used together. […] Proton therapy delivers high doses of radiation directly to the tumor without damaging surrounding healthy tissue. […] Bone marrow transplants (also called stem cell transplants) may be recommended if a patients condition does not respond to chemotherapy or if it returns.

• #74 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  High-dose therapy with autologous stem cell rescue (HDT/ASCR) is used as salvage therapy in patients with relapsed or refractory DLBCL. […] Chimeric antigen receptor (CAR) T-cell therapy has emerged as a preferred treatment for patients who do not wish to undergo HDT/ASCR. […] For second-line therapy of patients who do not intend to proceed with HDT/ASCR, the following regimens are listed as preferred by the NCCN. […] Nonchemotherapy options such as ibrutinib or lenalidomide-rituximab may be considered in certain circumstances. […] The US Food and Drug Administration (FDA) recently approved new treatments for patients with relapsed/refractory DLBCL after at least 2 prior lines of therapy, including epcoritamab-bysp (Epkinly) in May 2023 and glofitamab-gxbm (Columvi) in June 2023. […] The preferred first-line treatments for patients with follicular lymphoma include bendamustine+obinutuzumab or rituximab; CHOP+obinutuzumab or rituximab; CVP (cyclophosphamide, vincristine sulfate, prednisone)+obinutuzumab or rituximab; or lenalidomide+rituximab.

• #75 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  Treatments for previously untreated patients include: R-CHOP (rituximab [Rituxan], cyclophosphamide [Cytoxan], doxorubicin [hydroxydoxorubicin], Oncovin [vincristine] and prednisone). […] The standard treatment is a combination chemotherapy regimen, either with or without an autologous stem cell transplant. […] For most newly diagnosed cases of PTCL, the initial treatment is usually combination chemotherapy. Clinical trials are underway to study the efficacy and safety of potential new drugs and drug combinations to treat PTCL. […] Patients with PMBCL often need more intensive treatment. There are two standard combination regimens: R-EPOCH and R-CHOP. The R-EPOCH regimen is being used more often as a treatment for PMBCL, as there is less need for radiation therapy with this regimen. Treatment for people whose disease is refractory to treatment or has relapsed includes the monoclonal antibody pembrolizumab (Keytruda), and the CAR T-cell therapy products axicabtagene ciloleucel (Yescarta) and lisocabtagene maraleucel (Breyanzi).

• #76 Non-Hodgkin Lymphoma (NHL) Treatment & Management: Approach Considerations, Management of Indolent NHL, Management of Aggressive NHL

  https://emedicine.medscape.com/article/203399-treatment

  Randomized trials have shown that adding rituximab to chemotherapy regimens results in higher response rates, longer time to progression, and longer survival than chemotherapy. […] Maintenance therapy with rituximab after induction chemotherapy has been reported to prolong progression-free survival (PFS) in comparison with observation alone in patients with indolent lymphoma. […] In patients with indolent NHL that is refractory to rituximab, obinutuzumab plus bendamustine followed by obinutuzumab maintenance has improved efficacy over bendamustine monotherapy, with manageable toxicity. […] High-dose chemotherapy plus stem-cell transplantation is the treatment of choice for patients who have recurrent aggressive lymphomas. […] In 2019, polatuzumab vedotin, a CD79b-directed antibody-drug conjugate, gained accelerated approval from the FDA for use in combination with bendamustine and a rituximab product for adults with relapsed or recurrent DLBCL who have received at least 2 prior therapies and are not candidates for transplantation.

• #77 logo–sylvester

  https://umiamihealth.org/en/sylvester-comprehensive-cancer-center/treatments-and-services/hematologic-(blood)-cancers-/non-hodgkin-lymphoma

  The most common lymphoma is non-Hodgkin lymphoma (NHL), which has 35 different subtypes. These variations help us to determine the best treatment for your exact case. There are aggressive (fast-growing) and low-grade or indolent lymphomas. […] Aggressive lymphomas include: Burkitts lymphoma: This form of non-Hodgkin’s lymphoma starts in immune cells called B-cells. Burkitt lymphoma is the fastest growing human tumor. It is associated with impaired immunity and progresses rapidly if left untreated. […] Diffuse large B-cell lymphoma (DLBL): DLBL is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults. […] Mantle cell lymphoma: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma. It often starts by enlarging lymph nodes. It spreads to other tissues such as the bone marrow, liver, and gastrointestinal tract.

• #78 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  The following treatment recommendations established by the National Comprehensive Cancer Network (NCCN) offer guidance on induction therapy, maintenance therapy, and treatment for relapsed or refractory disease for the most common types of B-cell lymphoma. […] Cure is possible for a substantial number of patients with Burkitt lymphoma by using dose-intensive multiagent chemotherapy regimens. However, this type of cancer grows very quickly, so immediate treatment is important. More than half of people with Burkitt lymphoma can be cured with intensive chemotherapy. […] Treatment recommendations from the NCCN involve chemotherapy and central nervous system prophylaxis with intrathecal chemotherapy. […] First-line treatment recommendations for patients with stage I to II DLBCL (excluding stage II with extensive mesenteric disease) include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or pola-R-CHP (polatuzumab vedotin-piiq, rituximab, cyclophosphamide, doxorubicin, prednisone).

• #79 Non-Hodgkin Lymphoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559328/

  Non-Hodgkin lymphoma is a group of malignant neoplasms originating from lymphoid tissues, mainly the lymph nodes. […] This activity describes the evaluation and management of non-Hodgkin Lymphoma and explains the interprofessional team’s role in evaluating and treating patients with this condition. […] The treatment of NHL varies greatly, depending on tumor stage, grade, type of lymphoma, and various patient factors (eg, symptoms, age, performance status). […] Treatment of NHL is based on the type, stage, histopathological features, and symptoms. The most common treatments include chemotherapy, radiotherapy, immunotherapy, stem cell transplant, and, in rare cases, surgery. Chemoimmunotherapy, i.e., rituximab, is most commonly used in combination with chemotherapy. […] In Stage I or II, the R-CHOP regimen is often given for 3 to 6 cycles, with/without radiation therapy to the lymph node that is affected. In stage III or IV, 6 cycles of R-CHOP is the preferred treatment.

• #80 Non-Hodgkin Lymphoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559328/

  Non-Hodgkin lymphoma is a group of malignant neoplasms originating from lymphoid tissues, mainly the lymph nodes. […] This activity describes the evaluation and management of non-Hodgkin Lymphoma and explains the interprofessional team’s role in evaluating and treating patients with this condition. […] The treatment of NHL varies greatly, depending on tumor stage, grade, type of lymphoma, and various patient factors (eg, symptoms, age, performance status). […] Treatment of NHL is based on the type, stage, histopathological features, and symptoms. The most common treatments include chemotherapy, radiotherapy, immunotherapy, stem cell transplant, and, in rare cases, surgery. Chemoimmunotherapy, i.e., rituximab, is most commonly used in combination with chemotherapy. […] In Stage I or II, the R-CHOP regimen is often given for 3 to 6 cycles, with/without radiation therapy to the lymph node that is affected. In stage III or IV, 6 cycles of R-CHOP is the preferred treatment.

• #81 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  High-dose therapy with autologous stem cell rescue (HDT/ASCR) is used as salvage therapy in patients with relapsed or refractory DLBCL. […] Chimeric antigen receptor (CAR) T-cell therapy has emerged as a preferred treatment for patients who do not wish to undergo HDT/ASCR. […] For second-line therapy of patients who do not intend to proceed with HDT/ASCR, the following regimens are listed as preferred by the NCCN. […] Nonchemotherapy options such as ibrutinib or lenalidomide-rituximab may be considered in certain circumstances. […] The US Food and Drug Administration (FDA) recently approved new treatments for patients with relapsed/refractory DLBCL after at least 2 prior lines of therapy, including epcoritamab-bysp (Epkinly) in May 2023 and glofitamab-gxbm (Columvi) in June 2023. […] The preferred first-line treatments for patients with follicular lymphoma include bendamustine+obinutuzumab or rituximab; CHOP+obinutuzumab or rituximab; CVP (cyclophosphamide, vincristine sulfate, prednisone)+obinutuzumab or rituximab; or lenalidomide+rituximab.

• #82 logo–sylvester

  https://umiamihealth.org/en/sylvester-comprehensive-cancer-center/treatments-and-services/hematologic-(blood)-cancers-/non-hodgkin-lymphoma

  Lymphoblastic lymphoma: Lymphoblastic lymphoma is an aggressive but rare form of non-Hodgkin lymphoma. It usually develops from T-lymphocytes but occasionally from B-lymphocytes. Clinically, lymphoblastic lymphoma behaves like acute lymphoblastic leukemia (ALL), so they are treated in similar ways. […] Low-grade or indolent lymphomas include: Follicular lymphoma: It develops when the body makes abnormal B-lymphocytes and builds up in lymph nodes. […] Marginal zone lymphoma: Mucosa-associated lymphoid tissue (MALT) lymphoma is the most common form of marginal zone lymphoma. It occurs outside the lymph nodes and is capable of affecting any organ. Other subtypes include splenic and nodal marginal zone lymphoma. […] The most common types of treatment include: Chemotherapy: Chemotherapy involves taking one or more drugs by oral pill form or intravenously to kill lymphoma cells throughout your body. You may have this treatment along with other types of treatment.

• #83 Non-Hodgkin Lymphoma Treatment – NCI

  https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq

  Treatment of indolent stage I and indolent, contiguous stage II non-Hodgkin lymphoma may include the following: Radiation therapy, Monoclonal antibody therapy (rituximab) and/or chemotherapy, Watchful waiting. […] Treatment of aggressive stage I and aggressive, contiguous stage II non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab) and combination chemotherapy. […] Treatment of aggressive, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab) with combination chemotherapy, Combination chemotherapy. […] Treatment of recurrent non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab or obinutuzumab) with or without chemotherapy, Lenalidomide and rituximab, EZH2 inhibitor therapy (tazemetostat), Radiation therapy as palliative therapy to relieve symptoms and improve quality of life.

• #84 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  High-dose therapy with autologous stem cell rescue (HDT/ASCR) is used as salvage therapy in patients with relapsed or refractory DLBCL. […] Chimeric antigen receptor (CAR) T-cell therapy has emerged as a preferred treatment for patients who do not wish to undergo HDT/ASCR. […] For second-line therapy of patients who do not intend to proceed with HDT/ASCR, the following regimens are listed as preferred by the NCCN. […] Nonchemotherapy options such as ibrutinib or lenalidomide-rituximab may be considered in certain circumstances. […] The US Food and Drug Administration (FDA) recently approved new treatments for patients with relapsed/refractory DLBCL after at least 2 prior lines of therapy, including epcoritamab-bysp (Epkinly) in May 2023 and glofitamab-gxbm (Columvi) in June 2023. […] The preferred first-line treatments for patients with follicular lymphoma include bendamustine+obinutuzumab or rituximab; CHOP+obinutuzumab or rituximab; CVP (cyclophosphamide, vincristine sulfate, prednisone)+obinutuzumab or rituximab; or lenalidomide+rituximab.

• #85 Non-Hodgkin Lymphoma Treatment – NCI

  https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq

  Treatment of indolent stage I and indolent, contiguous stage II non-Hodgkin lymphoma may include the following: Radiation therapy, Monoclonal antibody therapy (rituximab) and/or chemotherapy, Watchful waiting. […] Treatment of aggressive stage I and aggressive, contiguous stage II non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab) and combination chemotherapy. […] Treatment of aggressive, noncontiguous stage II, III, or IV non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab) with combination chemotherapy, Combination chemotherapy. […] Treatment of recurrent non-Hodgkin lymphoma may include the following: Monoclonal antibody therapy (rituximab or obinutuzumab) with or without chemotherapy, Lenalidomide and rituximab, EZH2 inhibitor therapy (tazemetostat), Radiation therapy as palliative therapy to relieve symptoms and improve quality of life.

• #86 logo–sylvester

  https://umiamihealth.org/en/sylvester-comprehensive-cancer-center/treatments-and-services/hematologic-(blood)-cancers-/non-hodgkin-lymphoma

  The most common lymphoma is non-Hodgkin lymphoma (NHL), which has 35 different subtypes. These variations help us to determine the best treatment for your exact case. There are aggressive (fast-growing) and low-grade or indolent lymphomas. […] Aggressive lymphomas include: Burkitts lymphoma: This form of non-Hodgkin’s lymphoma starts in immune cells called B-cells. Burkitt lymphoma is the fastest growing human tumor. It is associated with impaired immunity and progresses rapidly if left untreated. […] Diffuse large B-cell lymphoma (DLBL): DLBL is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults. […] Mantle cell lymphoma: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma. It often starts by enlarging lymph nodes. It spreads to other tissues such as the bone marrow, liver, and gastrointestinal tract.

• #87 Non-Hodgkin Lymphoma | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/non-hodgkin-lymphoma

  Expert Care and Treatment for Lymphomas. The Lymphoma Program within the Hematologic Oncology Treatment Center includes specialists who treat patients with non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), B-cell neoplasms, and T-cell neoplasms. Your care team will collaborate to develop a comprehensive, personalized treatment plan that offers the most advanced therapies and an array of supportive resources. […] The treatments for indolent and aggressive lymphoma are different. […] Chemotherapy is often very effective in treating this type of lymphoma. […] Some cases of mantle cell lymphoma can be indolent; people do not have signs or symptoms and may not need treatment right away. However, in some cases aggressive treatment is needed. […] Familiarity with each type is critical to determining the appropriate treatment.

• #88 Non-Hodgkin Lymphoma | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/non-hodgkin-lymphoma

  Expert Care and Treatment for Lymphomas. The Lymphoma Program within the Hematologic Oncology Treatment Center includes specialists who treat patients with non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), B-cell neoplasms, and T-cell neoplasms. Your care team will collaborate to develop a comprehensive, personalized treatment plan that offers the most advanced therapies and an array of supportive resources. […] The treatments for indolent and aggressive lymphoma are different. […] Chemotherapy is often very effective in treating this type of lymphoma. […] Some cases of mantle cell lymphoma can be indolent; people do not have signs or symptoms and may not need treatment right away. However, in some cases aggressive treatment is needed. […] Familiarity with each type is critical to determining the appropriate treatment.

• #89 Non-Hodgkin Lymphoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559328/

  The most effective treatment is a high-dose methotrexate-based chemotherapy regimen. […] Mantle cell lymphoma with multiple areas of involvement is commonly treated with aggressive chemotherapy plus rituximab in eligible patients. […] This type of lymphoma has an indolent nature, and it shows a good response to treatment but is quite difficult to cure. […] This is a very fast-growing lymphoma. Some examples of chemo regimens used for this lymphoma include Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin [Adriamycin], and dexamethasone) alternating with high dose methotrexate and cytarabine (ara-C) + rituximab. […] Patients with HIV tend to have more aggressive forms of lymphoma, such as diffuse large B-cell lymphoma, primary CNS lymphoma, or Burkitt lymphoma. The use of highly active antiretroviral therapy (HAART) to treat HIV in addition to chemotherapyimmunotherapy is usually employed.

• #90 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  For patients with relapsed or refractory follicular lymphoma, the following treatment regimens are preferred, per the NCCN. […] Depending on whether aggressive induction therapy or less aggressive induction therapy is more appropriate, preferred treatment regimens vary. […] Patients with relapsed or refractory disease may receive second-line treatment with the following preferred regimens. […] When the disease progresses after prior covalent BTK inhibitor therapy, the noncovalent BTK inhibitor pirtobrutinib may be used. Alternatively, CAR T-cell therapy may be an option, including brexucabtagene autoleucel and lisocabtagene maraleucel. […] The NCCN provides treatment guidelines for first-line and second-line therapies for patients with these conditions. […] The following tables detail chemotherapy and combination regimens, small molecule inhibitors, and CAR T-cell therapies used to treat patients with NHL. […] Combination therapies often have better results than monotherapies because different drugs attack and kill cancer cells in different ways. […] The NCCN guidelines specify that an FDA-approved biosimilar is an appropriate substitute for rituximab throughout these treatment regimens.

• #91 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  For patients with relapsed or refractory follicular lymphoma, the following treatment regimens are preferred, per the NCCN. […] Depending on whether aggressive induction therapy or less aggressive induction therapy is more appropriate, preferred treatment regimens vary. […] Patients with relapsed or refractory disease may receive second-line treatment with the following preferred regimens. […] When the disease progresses after prior covalent BTK inhibitor therapy, the noncovalent BTK inhibitor pirtobrutinib may be used. Alternatively, CAR T-cell therapy may be an option, including brexucabtagene autoleucel and lisocabtagene maraleucel. […] The NCCN provides treatment guidelines for first-line and second-line therapies for patients with these conditions. […] The following tables detail chemotherapy and combination regimens, small molecule inhibitors, and CAR T-cell therapies used to treat patients with NHL. […] Combination therapies often have better results than monotherapies because different drugs attack and kill cancer cells in different ways. […] The NCCN guidelines specify that an FDA-approved biosimilar is an appropriate substitute for rituximab throughout these treatment regimens.

• #92 logo–sylvester

  https://umiamihealth.org/en/sylvester-comprehensive-cancer-center/treatments-and-services/hematologic-(blood)-cancers-/non-hodgkin-lymphoma

  The most common lymphoma is non-Hodgkin lymphoma (NHL), which has 35 different subtypes. These variations help us to determine the best treatment for your exact case. There are aggressive (fast-growing) and low-grade or indolent lymphomas. […] Aggressive lymphomas include: Burkitts lymphoma: This form of non-Hodgkin’s lymphoma starts in immune cells called B-cells. Burkitt lymphoma is the fastest growing human tumor. It is associated with impaired immunity and progresses rapidly if left untreated. […] Diffuse large B-cell lymphoma (DLBL): DLBL is a cancer of B cells, a type of white blood cell responsible for producing antibodies. It is the most common type of non-Hodgkin lymphoma among adults. […] Mantle cell lymphoma: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma. It often starts by enlarging lymph nodes. It spreads to other tissues such as the bone marrow, liver, and gastrointestinal tract.

• #93 Non-Hodgkin Lymphoma Treatment & Pharmacologic Management

  https://www.cancertherapyadvisor.com/ddi/non-hodgkin-lymphoma-pharmacological-treatment/

  The following treatment recommendations established by the National Comprehensive Cancer Network (NCCN) offer guidance on induction therapy, maintenance therapy, and treatment for relapsed or refractory disease for the most common types of B-cell lymphoma. […] Cure is possible for a substantial number of patients with Burkitt lymphoma by using dose-intensive multiagent chemotherapy regimens. However, this type of cancer grows very quickly, so immediate treatment is important. More than half of people with Burkitt lymphoma can be cured with intensive chemotherapy. […] Treatment recommendations from the NCCN involve chemotherapy and central nervous system prophylaxis with intrathecal chemotherapy. […] First-line treatment recommendations for patients with stage I to II DLBCL (excluding stage II with extensive mesenteric disease) include RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or pola-R-CHP (polatuzumab vedotin-piiq, rituximab, cyclophosphamide, doxorubicin, prednisone).

• #94 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  Doctors typically use highly aggressive chemotherapy that often require admission to the hospital to treat this subtype of NHL. Commonly used regimens include: CODOX-M/IVAC (cyclophosphamide, vincristine [Oncovin], doxorubicin and high-dose methotrexate) alternating with IVAC (ifosfamide, etoposide and highdose cytarabine). […] Studies report that BL is curable in a significant group of patients when treated with high-dose, multidrug chemotherapy regimens that include central nervous system (CNS) prophylaxis. About 60 to 90 percent of children and young adults with the disease achieve durable remissions if treated timely and appropriately. […] Standard treatment may include chemotherapy that includes intrathecal methotrexate, corticosteroid drugs and/or radiation therapy. Immunotherapy and high-dose chemotherapy with stem cell transplantation are being studied in clinical trials.

• #95 Non-Hodgkin Lymphoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK559328/

  The most effective treatment is a high-dose methotrexate-based chemotherapy regimen. […] Mantle cell lymphoma with multiple areas of involvement is commonly treated with aggressive chemotherapy plus rituximab in eligible patients. […] This type of lymphoma has an indolent nature, and it shows a good response to treatment but is quite difficult to cure. […] This is a very fast-growing lymphoma. Some examples of chemo regimens used for this lymphoma include Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin [Adriamycin], and dexamethasone) alternating with high dose methotrexate and cytarabine (ara-C) + rituximab. […] Patients with HIV tend to have more aggressive forms of lymphoma, such as diffuse large B-cell lymphoma, primary CNS lymphoma, or Burkitt lymphoma. The use of highly active antiretroviral therapy (HAART) to treat HIV in addition to chemotherapyimmunotherapy is usually employed.

• #96 https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  https://www.lls.org/lymphoma/non-hodgkin-lymphoma/nhl-subtypes/treatment-aggressive-nhl-subtypes

  Doctors typically use highly aggressive chemotherapy that often require admission to the hospital to treat this subtype of NHL. Commonly used regimens include: CODOX-M/IVAC (cyclophosphamide, vincristine [Oncovin], doxorubicin and high-dose methotrexate) alternating with IVAC (ifosfamide, etoposide and highdose cytarabine). […] Studies report that BL is curable in a significant group of patients when treated with high-dose, multidrug chemotherapy regimens that include central nervous system (CNS) prophylaxis. About 60 to 90 percent of children and young adults with the disease achieve durable remissions if treated timely and appropriately. […] Standard treatment may include chemotherapy that includes intrathecal methotrexate, corticosteroid drugs and/or radiation therapy. Immunotherapy and high-dose chemotherapy with stem cell transplantation are being studied in clinical trials.

• #97 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Side effects of non-Hodgkin lymphoma treatment. All treatments can cause side effects. However, the type and severity will vary between individuals, depending on the type of treatment used and how an individual responds to it. In general, more intensive treatment is associated with more severe side effects. It is important to report any symptoms you are having to your doctor or nurse. In most cases they can be treated and are reversible. […] What are the side effects of non-Hodgkin lymphoma treatment? Radiotherapy can cause similar side effects to those caused by chemotherapy including nausea and vomiting, hair loss and fatigue. In general, the type of side effects seen with radiotherapy depends on the area of the body which has been treated. Skin reactions are common. […] Chemotherapy kills cells that multiply quickly, such as lymphoma cells. It also causes damage to fast-growing normal cells, including hair cells and cells that make up the tissues in your mouth, gut and bone marrow. The side effects of chemotherapy occur as a result of this damage.

• #98 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Side effects of non-Hodgkin lymphoma treatment. All treatments can cause side effects. However, the type and severity will vary between individuals, depending on the type of treatment used and how an individual responds to it. In general, more intensive treatment is associated with more severe side effects. It is important to report any symptoms you are having to your doctor or nurse. In most cases they can be treated and are reversible. […] What are the side effects of non-Hodgkin lymphoma treatment? Radiotherapy can cause similar side effects to those caused by chemotherapy including nausea and vomiting, hair loss and fatigue. In general, the type of side effects seen with radiotherapy depends on the area of the body which has been treated. Skin reactions are common. […] Chemotherapy kills cells that multiply quickly, such as lymphoma cells. It also causes damage to fast-growing normal cells, including hair cells and cells that make up the tissues in your mouth, gut and bone marrow. The side effects of chemotherapy occur as a result of this damage.

• #99 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Side effects of non-Hodgkin lymphoma treatment. All treatments can cause side effects. However, the type and severity will vary between individuals, depending on the type of treatment used and how an individual responds to it. In general, more intensive treatment is associated with more severe side effects. It is important to report any symptoms you are having to your doctor or nurse. In most cases they can be treated and are reversible. […] What are the side effects of non-Hodgkin lymphoma treatment? Radiotherapy can cause similar side effects to those caused by chemotherapy including nausea and vomiting, hair loss and fatigue. In general, the type of side effects seen with radiotherapy depends on the area of the body which has been treated. Skin reactions are common. […] Chemotherapy kills cells that multiply quickly, such as lymphoma cells. It also causes damage to fast-growing normal cells, including hair cells and cells that make up the tissues in your mouth, gut and bone marrow. The side effects of chemotherapy occur as a result of this damage.

• #100 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  The side effects of radiotherapy and chemotherapy can include: […] Effects on the bone marrow. Chemotherapy affects the bone marrow’s ability to produce adequate numbers of blood cells. As a result, your blood count (the number of white cells, platelets and red cells circulating in your blood) will generally fall within a week of treatment. The length of time it takes for your bone marrow and blood counts to recover mainly depends on the type of chemotherapy given. […] When your platelet count is very low (thrombocytopenic) you can bruise and bleed more easily. In many cases a transfusion of platelets is given to reduce the risk of bleeding until the platelet count recovers. […] If your red blood cell count and haemoglobin levels drop you will probably become anaemic. When you are anaemic you feel more tired and lethargic than usual. If your haemoglobin level is very low, your doctor may prescribe a blood transfusion.

• #101 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Parotitis. Associated with radiotherapy, parotitis is an inflammation of the saliva-producing glands in the mouth, which can occur if these glands are within the treatment field used. These include the parotid or submandibular glands, which are situated at the top of the jaw line, in front of the ears. Parotitis causes dryness of the mouth and jaw pain, which usually settles down within a few days, once the inflammation subsides. […] Risk of infection. The point at which your white blood cell count is at its lowest is called the nadir. This is usually expected 10-14 days after having your chemotherapy. During this time you will be at a higher risk of developing an infection. At this stage you will also be neutropenic, which means that your neutrophil count is low. […] Neutrophils are important white blood cells that help us to fight infection. While your white blood cell count is low you should take sensible precautions to help prevent infection. These include avoiding crowds, avoiding close contact with people with infections who are contagious (for example colds, flu, chicken pox) and only eating food that has been properly prepared and cooked. If you do develop an infection you may experience a fever, which may or may not be accompanied by an episode of shivering where you shake uncontrollably. Infections while you are neutropenic can be quite serious and need to be treated with antibiotics as soon as possible. Sometimes your doctor may decide to use a drug to help the recovery of your neutrophil count. This drug works by stimulating the bone marrow to increase the production of neutrophils and is usually given as an injection under the skin (subcutaneous).

• #102 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  The side effects of radiotherapy and chemotherapy can include: […] Effects on the bone marrow. Chemotherapy affects the bone marrow’s ability to produce adequate numbers of blood cells. As a result, your blood count (the number of white cells, platelets and red cells circulating in your blood) will generally fall within a week of treatment. The length of time it takes for your bone marrow and blood counts to recover mainly depends on the type of chemotherapy given. […] When your platelet count is very low (thrombocytopenic) you can bruise and bleed more easily. In many cases a transfusion of platelets is given to reduce the risk of bleeding until the platelet count recovers. […] If your red blood cell count and haemoglobin levels drop you will probably become anaemic. When you are anaemic you feel more tired and lethargic than usual. If your haemoglobin level is very low, your doctor may prescribe a blood transfusion.

• #103 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  The side effects of radiotherapy and chemotherapy can include: […] Effects on the bone marrow. Chemotherapy affects the bone marrow’s ability to produce adequate numbers of blood cells. As a result, your blood count (the number of white cells, platelets and red cells circulating in your blood) will generally fall within a week of treatment. The length of time it takes for your bone marrow and blood counts to recover mainly depends on the type of chemotherapy given. […] When your platelet count is very low (thrombocytopenic) you can bruise and bleed more easily. In many cases a transfusion of platelets is given to reduce the risk of bleeding until the platelet count recovers. […] If your red blood cell count and haemoglobin levels drop you will probably become anaemic. When you are anaemic you feel more tired and lethargic than usual. If your haemoglobin level is very low, your doctor may prescribe a blood transfusion.

• #104 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Nausea and vomiting. Nausea and vomiting are often associated with chemotherapy and some forms of radiotherapy. These days however, thanks to significant improvements in anti-sickness (anti-emetic) drugs, nausea and vomiting are generally very well controlled. You will be given anti-sickness drugs before and for a few days after your chemotherapy treatment. Be sure to tell the nurses and doctors if the anti-emetics are not working for you and you still feel sick. Some people find that eating smaller meals more frequently during the day, rather than a few large meals, helps to reduce nausea and vomiting. Many find that eating cool or cold food is more palatable, for example jelly or custard. Drinking ginger ale or soda water and eating dry toast may also help if you are feeling sick. […] Changes in taste and smell. Both chemotherapy and radiation therapy can cause changes to your sense of taste and smell. This is usually temporary but in some cases it lasts up to several months.

• #105 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Mucositis. Mucositis, or inflammation of the lining of the mouth, throat or gut is a common and uncomfortable side effect of chemotherapy and some forms of radiotherapy. It usually starts about a week after the treatment has finished and goes away once your blood count recovers, usually a couple of weeks later. During this time your mouth and throat could get quite sore. Soluble pain medication and other topical drugs (ones which can be applied to the sore area) can help. If the pain becomes more severe, stronger pain killers might be needed. It is important to keep your mouth as clean as possible while you are having treatment to help prevent infection. Avoid commercial mouthwashes, as these are often too strong or may contain alcohol, which will hurt your mouth. […] Bowel changes. Chemotherapy can cause some damage to the lining of your bowel wall. This can lead to cramping, wind, abdominal swelling and diarrhoea. Be sure to tell the nurses and doctors if you experience any of these symptoms. If you are constipated or if you are feeling any discomfort or tenderness around your anus when you are trying to move your bowels, you may need a gentle laxative to help soften your bowel motions.

• #106 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Mucositis. Mucositis, or inflammation of the lining of the mouth, throat or gut is a common and uncomfortable side effect of chemotherapy and some forms of radiotherapy. It usually starts about a week after the treatment has finished and goes away once your blood count recovers, usually a couple of weeks later. During this time your mouth and throat could get quite sore. Soluble pain medication and other topical drugs (ones which can be applied to the sore area) can help. If the pain becomes more severe, stronger pain killers might be needed. It is important to keep your mouth as clean as possible while you are having treatment to help prevent infection. Avoid commercial mouthwashes, as these are often too strong or may contain alcohol, which will hurt your mouth. […] Bowel changes. Chemotherapy can cause some damage to the lining of your bowel wall. This can lead to cramping, wind, abdominal swelling and diarrhoea. Be sure to tell the nurses and doctors if you experience any of these symptoms. If you are constipated or if you are feeling any discomfort or tenderness around your anus when you are trying to move your bowels, you may need a gentle laxative to help soften your bowel motions.

• #107 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Hair loss. Hair loss is unfortunately a very common side effect of chemotherapy and some forms of radiotherapy. It is, however, usually only temporary. The hair can start to fall out within a couple of weeks of treatment and tends to grow back three to six months later. Avoiding using heat or chemicals and only using a soft hairbrush and a mild baby shampoo can help reduce the itchiness and scalp tenderness which can occur while you are losing your hair. You need to avoid direct sunlight on your exposed head (wear a hat) because chemotherapy and radiotherapy makes your skin even more vulnerable to the damaging effects of the sun (like sunburn and skin cancers). Remember that without your hair your head can get quite cold so a beanie might be useful. Hair can also be lost from your eyebrows, eyelashes, arms and legs.

• #108 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Fatigue. Most people experience some degree of tiredness in the days and weeks following chemotherapy and radiotherapy. Getting plenty of rest and doing a little light exercise each day may help to make you feel better during this time. It is important to listen to your body and rest when you are tired. […] Fertility. Some types of chemotherapy and radiotherapy may cause a temporary or permanent reduction in your fertility. If possible, before you commence treatment you should discuss any questions or concerns you might have regarding your future fertility with your doctor. In women, some types of chemotherapy and radiotherapy can cause varying degrees of damage to the normal functioning of the ovaries. […] In men, sperm production can be impaired for a while but the production of new sperm may become normal again in the future. There are some options for preserving your fertility, if necessary, while you are having treatment for lymphoma.

• #109 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Side effects of non-Hodgkin lymphoma treatment. All treatments can cause side effects. However, the type and severity will vary between individuals, depending on the type of treatment used and how an individual responds to it. In general, more intensive treatment is associated with more severe side effects. It is important to report any symptoms you are having to your doctor or nurse. In most cases they can be treated and are reversible. […] What are the side effects of non-Hodgkin lymphoma treatment? Radiotherapy can cause similar side effects to those caused by chemotherapy including nausea and vomiting, hair loss and fatigue. In general, the type of side effects seen with radiotherapy depends on the area of the body which has been treated. Skin reactions are common. […] Chemotherapy kills cells that multiply quickly, such as lymphoma cells. It also causes damage to fast-growing normal cells, including hair cells and cells that make up the tissues in your mouth, gut and bone marrow. The side effects of chemotherapy occur as a result of this damage.

• #110 Content – Health Encyclopedia – University of Rochester Medical Center

  https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=34&contentid=ALymT3

  Radiation treatment is a lot like getting an X-ray. It doesn’t hurt, and you don’t see the radiation during the treatment. […] You’ll likely need radiation treatment every day for 5 days in a row (Monday through Friday) for several weeks. […] The side effects of radiation depend on the part of your body being treated, the dose of radiation, and other factors. […] Common side effects include: Skin in the treatment field becomes dry, irritated, and sensitive. A reddened „sunburn” can develop, which may lead to blistering and peeling. […] Radiation to your chest, neck, or mouth area can cause: Dry mouth, which can be permanent (Ask your healthcare provider.) […] Total body radiation can cause: Low blood cell counts. […] Long-term side effects can include: Lung or heart damage, from radiation to your chest. […] An increased risk for another cancer in the treated area many years later.

• #111 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Parotitis. Associated with radiotherapy, parotitis is an inflammation of the saliva-producing glands in the mouth, which can occur if these glands are within the treatment field used. These include the parotid or submandibular glands, which are situated at the top of the jaw line, in front of the ears. Parotitis causes dryness of the mouth and jaw pain, which usually settles down within a few days, once the inflammation subsides. […] Risk of infection. The point at which your white blood cell count is at its lowest is called the nadir. This is usually expected 10-14 days after having your chemotherapy. During this time you will be at a higher risk of developing an infection. At this stage you will also be neutropenic, which means that your neutrophil count is low. […] Neutrophils are important white blood cells that help us to fight infection. While your white blood cell count is low you should take sensible precautions to help prevent infection. These include avoiding crowds, avoiding close contact with people with infections who are contagious (for example colds, flu, chicken pox) and only eating food that has been properly prepared and cooked. If you do develop an infection you may experience a fever, which may or may not be accompanied by an episode of shivering where you shake uncontrollably. Infections while you are neutropenic can be quite serious and need to be treated with antibiotics as soon as possible. Sometimes your doctor may decide to use a drug to help the recovery of your neutrophil count. This drug works by stimulating the bone marrow to increase the production of neutrophils and is usually given as an injection under the skin (subcutaneous).

• #112 Content – Health Encyclopedia – University of Rochester Medical Center

  https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=34&contentid=ALymT3

  Radiation treatment is a lot like getting an X-ray. It doesn’t hurt, and you don’t see the radiation during the treatment. […] You’ll likely need radiation treatment every day for 5 days in a row (Monday through Friday) for several weeks. […] The side effects of radiation depend on the part of your body being treated, the dose of radiation, and other factors. […] Common side effects include: Skin in the treatment field becomes dry, irritated, and sensitive. A reddened „sunburn” can develop, which may lead to blistering and peeling. […] Radiation to your chest, neck, or mouth area can cause: Dry mouth, which can be permanent (Ask your healthcare provider.) […] Total body radiation can cause: Low blood cell counts. […] Long-term side effects can include: Lung or heart damage, from radiation to your chest. […] An increased risk for another cancer in the treated area many years later.

• #113 Content – Health Encyclopedia – University of Rochester Medical Center

  https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=34&contentid=ALymT3

  Radiation treatment is a lot like getting an X-ray. It doesn’t hurt, and you don’t see the radiation during the treatment. […] You’ll likely need radiation treatment every day for 5 days in a row (Monday through Friday) for several weeks. […] The side effects of radiation depend on the part of your body being treated, the dose of radiation, and other factors. […] Common side effects include: Skin in the treatment field becomes dry, irritated, and sensitive. A reddened „sunburn” can develop, which may lead to blistering and peeling. […] Radiation to your chest, neck, or mouth area can cause: Dry mouth, which can be permanent (Ask your healthcare provider.) […] Total body radiation can cause: Low blood cell counts. […] Long-term side effects can include: Lung or heart damage, from radiation to your chest. […] An increased risk for another cancer in the treated area many years later.

• #114 Long Term Side-Effects of Non-Hodgkin’s Lymphoma Treatment

  https://www.healthline.com/health/non-hodgkins-lymphoma-treatment-side-effects

  R-CHOP is an abbreviation for a combination of chemotherapy medications that are often used to treat NHL. […] Any medication or treatment can have side effects, but chemotherapy, radiation, and stem cell transplantation have a particularly high risk of long-term and late side effects. […] Long-term side effects that appear right after treatment and can last for some time include conditions like fatigue, weakness, anemia, and reproductive changes. […] Late effects are side effects that appear sometime after treatment and may be permanent. Examples of the late effects of NHL treatment include: heart difficulties, infertility, bone density loss, nerve damage or neuropathy, secondary cancers, growth delays, developmental delays. […] Aside from the long-term and late side effects, there are immediate but short-lived side effects that are common with NHL treatment.

• #115 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Fatigue. Most people experience some degree of tiredness in the days and weeks following chemotherapy and radiotherapy. Getting plenty of rest and doing a little light exercise each day may help to make you feel better during this time. It is important to listen to your body and rest when you are tired. […] Fertility. Some types of chemotherapy and radiotherapy may cause a temporary or permanent reduction in your fertility. If possible, before you commence treatment you should discuss any questions or concerns you might have regarding your future fertility with your doctor. In women, some types of chemotherapy and radiotherapy can cause varying degrees of damage to the normal functioning of the ovaries. […] In men, sperm production can be impaired for a while but the production of new sperm may become normal again in the future. There are some options for preserving your fertility, if necessary, while you are having treatment for lymphoma.

• #116 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Fatigue. Most people experience some degree of tiredness in the days and weeks following chemotherapy and radiotherapy. Getting plenty of rest and doing a little light exercise each day may help to make you feel better during this time. It is important to listen to your body and rest when you are tired. […] Fertility. Some types of chemotherapy and radiotherapy may cause a temporary or permanent reduction in your fertility. If possible, before you commence treatment you should discuss any questions or concerns you might have regarding your future fertility with your doctor. In women, some types of chemotherapy and radiotherapy can cause varying degrees of damage to the normal functioning of the ovaries. […] In men, sperm production can be impaired for a while but the production of new sperm may become normal again in the future. There are some options for preserving your fertility, if necessary, while you are having treatment for lymphoma.

• #117 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Fatigue. Most people experience some degree of tiredness in the days and weeks following chemotherapy and radiotherapy. Getting plenty of rest and doing a little light exercise each day may help to make you feel better during this time. It is important to listen to your body and rest when you are tired. […] Fertility. Some types of chemotherapy and radiotherapy may cause a temporary or permanent reduction in your fertility. If possible, before you commence treatment you should discuss any questions or concerns you might have regarding your future fertility with your doctor. In women, some types of chemotherapy and radiotherapy can cause varying degrees of damage to the normal functioning of the ovaries. […] In men, sperm production can be impaired for a while but the production of new sperm may become normal again in the future. There are some options for preserving your fertility, if necessary, while you are having treatment for lymphoma.

• #118 Side effects of non-Hodgkin lymphoma treatment – Leukaemia Foundation

  https://www.leukaemia.org.au/blood-cancer/types-of-blood-cancer/lymphoma/non-hodgkin-lymphoma/treatment-side-effects/

  Early menopause. Some cancer treatments can affect the normal functioning of the ovaries. This can sometimes lead to infertility and an earlier than expected onset of menopause, even at a young age. The onset of menopause in these circumstances can be sudden and, understandably, very distressing. Hormone changes can lead to many of the classic symptoms of menopause. Some women experience decreased sexual drive, anxiety and even depressive symptoms during this time. It is important that you discuss any changes to your periods with your doctor or nurse. […] Body image, sexuality and sexual activity. Hair loss, skin changes and fatigue can all interfere with how you feel about yourself as a man or a woman and as a ‘sexual being’. During treatment you may experience a decrease in libido and it may take some time for things to return to ‘normal’. It’s perfectly reasonable and safe to have sex while you are on treatment or shortly afterwards, but there are some precautions you need to take. It is usually recommended that you or your partner do not become pregnant as some of the treatments given might harm the developing baby. As such, you need to ensure that you or your partner use a suitable form of contraception. Condoms are also necessary in the seven days following a treatment session, to ensure that your partner is not exposed to any residual drugs. Partners are sometimes afraid that sex might in some way harm the patient. This is not likely as long as the partner is free from any infections and the sex is relatively gentle.

• #119 Content – Health Encyclopedia – University of Rochester Medical Center

  https://www.urmc.rochester.edu/encyclopedia/content?contenttypeid=34&contentid=ALymT3

  Radiation treatment is a lot like getting an X-ray. It doesn’t hurt, and you don’t see the radiation during the treatment. […] You’ll likely need radiation treatment every day for 5 days in a row (Monday through Friday) for several weeks. […] The side effects of radiation depend on the part of your body being treated, the dose of radiation, and other factors. […] Common side effects include: Skin in the treatment field becomes dry, irritated, and sensitive. A reddened „sunburn” can develop, which may lead to blistering and peeling. […] Radiation to your chest, neck, or mouth area can cause: Dry mouth, which can be permanent (Ask your healthcare provider.) […] Total body radiation can cause: Low blood cell counts. […] Long-term side effects can include: Lung or heart damage, from radiation to your chest. […] An increased risk for another cancer in the treated area many years later.

• #120 Long Term Side-Effects of Non-Hodgkin’s Lymphoma Treatment

  https://www.healthline.com/health/non-hodgkins-lymphoma-treatment-side-effects

  R-CHOP is an abbreviation for a combination of chemotherapy medications that are often used to treat NHL. […] Any medication or treatment can have side effects, but chemotherapy, radiation, and stem cell transplantation have a particularly high risk of long-term and late side effects. […] Long-term side effects that appear right after treatment and can last for some time include conditions like fatigue, weakness, anemia, and reproductive changes. […] Late effects are side effects that appear sometime after treatment and may be permanent. Examples of the late effects of NHL treatment include: heart difficulties, infertility, bone density loss, nerve damage or neuropathy, secondary cancers, growth delays, developmental delays. […] Aside from the long-term and late side effects, there are immediate but short-lived side effects that are common with NHL treatment.

• #121 Long Term Side-Effects of Non-Hodgkin’s Lymphoma Treatment

  https://www.healthline.com/health/non-hodgkins-lymphoma-treatment-side-effects

  R-CHOP is an abbreviation for a combination of chemotherapy medications that are often used to treat NHL. […] Any medication or treatment can have side effects, but chemotherapy, radiation, and stem cell transplantation have a particularly high risk of long-term and late side effects. […] Long-term side effects that appear right after treatment and can last for some time include conditions like fatigue, weakness, anemia, and reproductive changes. […] Late effects are side effects that appear sometime after treatment and may be permanent. Examples of the late effects of NHL treatment include: heart difficulties, infertility, bone density loss, nerve damage or neuropathy, secondary cancers, growth delays, developmental delays. […] Aside from the long-term and late side effects, there are immediate but short-lived side effects that are common with NHL treatment.

• #122 What’s New in Lymphoma Treatments?

  https://www.oregoncancer.com/blog/whats-new-in-lymphoma-treatments

  Lymphoma treatment is quickly evolving for both non-Hodgkin lymphoma and Hodgkin lymphoma. The most recent lymphoma treatments focus on improving drug precision. Treatments like targeted therapies and immunotherapy make it possible to directly focus on specific types of cells and even specific abnormalities within the cells to stop the growth of cancer. […] Depending on the specific subtype of lymphoma, various treatments are available. Previously the primary option was chemotherapy. But cancer researchers, including our own oncologists in the Willamette Valley, have tested new treatment options for lymphomas through clinical trials including: […] Targeted therapy drugs identify and kill specific cancer cells. Because they precisely target a specific type of protein or genetic mutation, there’s less damage to healthy cells than chemotherapy or radiation therapy. The category of targeted therapy is rapidly expanding as researchers learn more about the various proteins and genetic changes in cancer cells that can be treated using this type of drug.

• #123 Treatment Options for Lymphoma | Lymphoma Research Foundation

  https://lymphoma.org/understanding-lymphoma/treatment-planning-and-options/treatments/

  Clinical trials are appropriate for patients at all stages of disease. […] The term immunotherapy (also called immune-oncology) refers to treatments that interact with the immune system. […] Radiation therapy (also called radiotherapy) uses high-energy x-rays to kill cancer cells and shrink tumors. […] The ability to transplant stem cells allows physicians to use higher doses of chemotherapy to treat the cancer than the body would normally tolerate, increasing the probability of killing cancer cells. […] Most types of targeted therapy help treat lymphoma by interfering with specific proteins that help tumors grow and spread throughout the body.

• #124 Treatment Options for Lymphoma | Lymphoma Research Foundation

  https://www.lymphoma.org/understanding-lymphoma/treatment-planning-and-options/treatments/

  Although indolent or slow-growing forms of non-Hodgkin lymphoma are not currently curable, the prognosis is still very good. Patients may live for 20 years or more following an initial diagnosis. In certain patients with an indolent form of the disease, treatment may not be necessary until there are signs of progression. Response to treatment can also change over time. Treatment that worked initially may be ineffective the next time, making it necessary to always keep abreast of the latest information on new or experimental treatment options. […] Clinical trials are appropriate for patients at all stages of disease. The purpose of a clinical trial is to safely monitor the effects of a drug on patients over time and to identify more effective therapies for specific diseases. By participating in a clinical trial, patients may or may not get access to the newest therapies but will receive quality care in a very carefully controlled and supportive environment.

• #125 Non-Hodgkin Lymphoma | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/diseases/non-hodgkin-lymphoma.html

  Physicians and scientists from Fred Hutch and UW Medicine are testing new treatments for non-Hodgkin lymphoma (NHL) and discovering new ways to use current NHL treatments. […] We have clinical trials for all stages of NHL, from early to advanced. These trials test dozens of medicines for different NHL subtypes. Some of the therapies we are studying are: Chemotherapy regimens, Antibody therapies and other targeted therapies, Immunotherapies, including cellular immunotherapies and checkpoint inhibitors. […] When your care team designs your treatment plan, they will give you the choice to join clinical trials that match your situation. If you decide to join one, you will see the same physicians and nurses as you would for standard therapy.

• #126 What’s New in Lymphoma Treatments?

  https://www.oregoncancer.com/blog/whats-new-in-lymphoma-treatments

  Immunotherapy, also called biologic therapy, uses the immune system to more effectively fight cancer. The body and lab-made substances help strengthen and guide the body’s natural defenses against cancer. […] The FDA has recently approved mosunetuzumab-axgb (Lunsumio), a new category of immunotherapy for advanced follicular lymphoma. This bispecific antibody is the first of its kind to treat follicular lymphoma, a type of non-Hodgkin lymphoma. This subtype of non-Hodgkin lymphoma has had limited treatment options, especially when patients do not respond to other treatment methods or the lymphoma has returned. Lunsumio works by engaging B and T cells to destroy cancer cells.

• #127 Non-Hodgkin Lymphoma | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/diseases/non-hodgkin-lymphoma.html

  Physicians and scientists from Fred Hutch and UW Medicine are testing new treatments for non-Hodgkin lymphoma (NHL) and discovering new ways to use current NHL treatments. […] We have clinical trials for all stages of NHL, from early to advanced. These trials test dozens of medicines for different NHL subtypes. Some of the therapies we are studying are: Chemotherapy regimens, Antibody therapies and other targeted therapies, Immunotherapies, including cellular immunotherapies and checkpoint inhibitors. […] When your care team designs your treatment plan, they will give you the choice to join clinical trials that match your situation. If you decide to join one, you will see the same physicians and nurses as you would for standard therapy.

• #128 Non-Hodgkin’s Lymphoma Treatment: Combination Therapy

  https://www.webmd.com/cancer/lymphoma/non-hodgkins-multiple-treatments

  Immunotherapy uses your own immune system to help treat cancer. While your doctor might prescribe this kind of treatment on its own, it can also be combined with other treatments like chemotherapy and radiation. […] Many people do better when chemo and immunotherapy are used together, but taking more than one medicine can cause more side effects. Combination therapies cost more, too. […] Right now, scientists are testing more than a thousand different combinations. It’s too soon to know if these are safe or work better than treatments we have now, but some doctors think immunotherapy is the future of cancer care. […] One of the most common treatments for non-Hodgkin’s lymphoma is a type of chemo called R-CHOP. […] Rituximab is sometimes added to other chemo treatments, too. Most use a combination of medications because each one attacks cancer in a different way.

• #129 Non-Hodgkin Lymphoma | Fred Hutchinson Cancer Center

  https://www.fredhutch.org/en/diseases/non-hodgkin-lymphoma.html

  Physicians and scientists from Fred Hutch and UW Medicine are testing new treatments for non-Hodgkin lymphoma (NHL) and discovering new ways to use current NHL treatments. […] We have clinical trials for all stages of NHL, from early to advanced. These trials test dozens of medicines for different NHL subtypes. Some of the therapies we are studying are: Chemotherapy regimens, Antibody therapies and other targeted therapies, Immunotherapies, including cellular immunotherapies and checkpoint inhibitors. […] When your care team designs your treatment plan, they will give you the choice to join clinical trials that match your situation. If you decide to join one, you will see the same physicians and nurses as you would for standard therapy.

• #130 Lymphoma: Symptoms, Causes and Treatment

  https://my.clevelandclinic.org/health/diseases/22225-lymphoma

  Lymphoma is a term for a group of blood cancers in your lymphatic system. Healthcare providers can successfully treat and often cure it. […] Often, treatment can put lymphoma into remission or cure it. […] Common lymphoma treatments include: Chemotherapy. Radiation therapy. Targeted therapy. Immunotherapy. CAR T-cell therapy. Stem cell (bone marrow) transplantation. […] Your provider may recommend palliative care as part of your treatment plan. Palliative care focuses on helping you manage symptoms and treatment side effects. It also offers support. […] That said, treatment often puts lymphoma into remission or cures the condition. Remission means you dont have lymphoma symptoms and tests dont find signs of lymphoma. […] Overall, survival rate data show 89% of people with Hodgkin lymphoma and 74% of people with non-Hodgkin lymphoma were alive five years after diagnosis. […] Lymphoma is a serious illness. Fortunately, lymphoma treatments continue to improve, helping people live longer. Each year, survival rates improve.

• #131

  https://www.nhs.uk/conditions/non-hodgkin-lymphoma/treatment/

  Non-Hodgkin lymphoma is usually treated with chemotherapy or radiotherapy, although some people may not need treatment straight away. […] The recommended treatment plan will depend on your general health and age, as many of the treatments can put a strain on the body. […] Discussions about your treatment plan will usually take place with several doctors and other health professionals who specialise in different aspects of treating lymphoma. […] Your MDT will recommend the best treatment options for you. […] If non-Hodgkin lymphoma is low grade (slow developing) and you’re well, a period of „watch and wait” is often recommended. […] Chemotherapy is a widely used treatment for non-Hodgkin lymphoma that involves using medicine to kill cancer cells. […] It may be used on its own, combined with biological therapy, or combined with radiotherapy.

• #132 Non-Hodgkin lymphoma – Wikipedia

  https://en.wikipedia.org/wiki/Non-Hodgkin_lymphoma

  Treatment depends on whether the lymphoma is slow or fast growing and if it is in one area or many areas. Treatments may include chemotherapy, radiation, immunotherapy, targeted therapy, stem-cell transplantation, surgery, or watchful waiting. […] The traditional treatment of NHL includes chemotherapy, radiotherapy, and stem-cell transplants. There have also been developments in immunotherapy used in the treatment of NHL. […] The most common chemotherapy used for B-cell non-Hodgkin lymphoma is R-CHOP, which is a regimen of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus rituximab. […] R-CHP with polatuzumab vedotin, an antibody-drug conjugate, was included as a category 1 preferred regimen for first-line DLBCL by the National Comprehensive Cancer Network in 2023. […] If participants receive stem-cell transplants, they can develop a graft-versus-host disease. […] Platelet transfusions may be necessary for those who receive chemotherapy or undergo a stem cell transplantation due to the higher risk for bleeding.

• #133 What’s New in Lymphoma Treatments?

  https://www.oregoncancer.com/blog/whats-new-in-lymphoma-treatments

  Lymphoma treatment is quickly evolving for both non-Hodgkin lymphoma and Hodgkin lymphoma. The most recent lymphoma treatments focus on improving drug precision. Treatments like targeted therapies and immunotherapy make it possible to directly focus on specific types of cells and even specific abnormalities within the cells to stop the growth of cancer. […] Depending on the specific subtype of lymphoma, various treatments are available. Previously the primary option was chemotherapy. But cancer researchers, including our own oncologists in the Willamette Valley, have tested new treatment options for lymphomas through clinical trials including: […] Targeted therapy drugs identify and kill specific cancer cells. Because they precisely target a specific type of protein or genetic mutation, there’s less damage to healthy cells than chemotherapy or radiation therapy. The category of targeted therapy is rapidly expanding as researchers learn more about the various proteins and genetic changes in cancer cells that can be treated using this type of drug.

• #134 Lymphoma: Symptoms, Causes and Treatment

  https://my.clevelandclinic.org/health/diseases/22225-lymphoma

  Lymphoma is a term for a group of blood cancers in your lymphatic system. Healthcare providers can successfully treat and often cure it. […] Often, treatment can put lymphoma into remission or cure it. […] Common lymphoma treatments include: Chemotherapy. Radiation therapy. Targeted therapy. Immunotherapy. CAR T-cell therapy. Stem cell (bone marrow) transplantation. […] Your provider may recommend palliative care as part of your treatment plan. Palliative care focuses on helping you manage symptoms and treatment side effects. It also offers support. […] That said, treatment often puts lymphoma into remission or cures the condition. Remission means you dont have lymphoma symptoms and tests dont find signs of lymphoma. […] Overall, survival rate data show 89% of people with Hodgkin lymphoma and 74% of people with non-Hodgkin lymphoma were alive five years after diagnosis. […] Lymphoma is a serious illness. Fortunately, lymphoma treatments continue to improve, helping people live longer. Each year, survival rates improve.

• #135 Lymphoma: Symptoms, Causes and Treatment

  https://my.clevelandclinic.org/health/diseases/22225-lymphoma

  Lymphoma is a term for a group of blood cancers in your lymphatic system. Healthcare providers can successfully treat and often cure it. […] Often, treatment can put lymphoma into remission or cure it. […] Common lymphoma treatments include: Chemotherapy. Radiation therapy. Targeted therapy. Immunotherapy. CAR T-cell therapy. Stem cell (bone marrow) transplantation. […] Your provider may recommend palliative care as part of your treatment plan. Palliative care focuses on helping you manage symptoms and treatment side effects. It also offers support. […] That said, treatment often puts lymphoma into remission or cures the condition. Remission means you dont have lymphoma symptoms and tests dont find signs of lymphoma. […] Overall, survival rate data show 89% of people with Hodgkin lymphoma and 74% of people with non-Hodgkin lymphoma were alive five years after diagnosis. […] Lymphoma is a serious illness. Fortunately, lymphoma treatments continue to improve, helping people live longer. Each year, survival rates improve.

Zobacz więcej